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ABSTRACT OF THE THESIS
IN VITRO EFFECT OF SHARK CARTILAGE
ON HUMAN LEUKOCYTE FUNCTION

by
Aline Comelissen
Florida International University, 2001
Miami, Florida
Professor Sylvia L. Smith, Major Professor
Previous in vitro studies have shown that shark cartilage extracts stimulate human
leukocytes to release significant levels of TNFa, a cytokine typical of a Thl immune
response. The purpose of this study was to investigate further the effects of shark
cartilage on cellular immune function, particularly cell proliferation, apoptosis, and IL-4
and INFy production. The viability and proliferation of cell cultures grown in the
presence of shark cartilage extract was not significantly different from unstimulated
control cultures or those stimulated with mitogens (Con A, PMA, LPS), respectively. The
effect of shark cartilage on apoptosis was determined by microscopic analysis of
morphological apoptotic changes and by the detection of DNA fragmentation observed as
characteristic ladder formation in agarose gel electrophoresis. While DNA fragmentation
could not be demonstrated for cartilage-stimulated cells, characteristic morphological
changes, indicative of apoptosis, were observed in leukocytes following incubation with
shark cartilage extract. A statistically significant difference was not noted in the number
of apoptotic cells present in cartilage-stimulated leukocytes and those stimulated with 0.5

pM/ml of staurosporine, suggesting that apoptosis is induced in the presence of cartilage
extract. Culture supernatants of cartilage-stimulated leukocytes were assayed for IL-4 and
IFN-y by enzyme-linked immunosorbent assay (ELISA). Although a low level of IL-4
and INFy was detected in culture supernatants of Con A and PMA stimulated cells it was
not significantly different from that of unstimulated control cultures. Thus the
significance of the absence of detectable IL-4 or INFy in supernatants of cartilagestimulated cultures could not be determined. However, as previously shown, supernatants
did contain TNFa. Results of the study did not show a definitive pattern of cytokine
production, characteristic of either a Thl or Th2 type immune response.
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In tro d u c tio n
Shark cartilage therapy has been widely used for the treatment of a variety of
chronic diseases. It is used as an anti-inflammatory agent, in wound healing and also for
prophylactic purposes. During a conference sponsored by the National Institutes of
Health (NIH) on alternative therapies in 1992, researchers reported that about 50,000
Americans were using shark cartilage and that these numbers were expected to increase
through the following years (Workshop on Alternative Medicine. Washington, DC: US
Government Printing Office; 1992). However, there is no direct evidence that shark
cartilage offers any benefit in the treatment of human diseases or as a prophylactic agent.
An earlier study carried out in our laboratory showed that an acid extract of shark
cartilage, prepared from a commercial source of cartilage, stimulated human leukocytes
to release significant levels of TNF-a. TNF-a is a cytokine characteristic of a Th-1
response, which represents an inflammatory response. It is not known what other
cytokines are induced by shark cartilage and whether the cellular response is associated
with the activation of any particular cell type or the production of particular cytokines.
IL-4 plays an important biological role in cell-cell communucation as it modulates
cytokine production by many cells of the immune system. Unlike TNF-a, IL-4 is a
cytokine that typically induces in vivo a Th-2 response, i.e. an anti-inflammatory
response.
The purpose of this study is to further investigate the effects of shark cartilage on
cellular immune function. The proposed research will primarily focus on the secretion of
IL-4 and IFN-y by shark cartilage-stimulated human leukocytes and will also examine in

vitro the effect of shark cartilage on apoptosis, proliferation and viability of human
leukocytes. Human leukocytes and a peripheral blood mononuclear cell-enriched fraction
of leukocytes will be cultured in the presence of shark cartilage, and culture supernatants
will be assayed for IL-4, IFN-y and TNF-a, which will be detected by enzyme-linked
immunosorbent assay (ELISA). The assessment of apoptosis will be made through
analysis of morphological apoptotic changes observed by light microscopy, and by the
detection of DNA fragmentation with characteristic ladder formation in agarose gel
electrophoresis. Proliferation will be measured by the MTT assay and by manual cell
count.

B ackground
During the last decade, as an alternative to conventional medicine, scientists have
been searching for new effective methods for the treatment and prevention of diseases,
such as cancer, AIDS, autoimmune diseases and other chronic, degenerative diseases.
Alternative Medicine, also referred to as Complementary Medicine, is defined by
Eisenberg et al. (1993) as treatments and health care practices not taught widely in
medical schools, not generally used in hospitals, and not usually reimbursed by medical
insurance companies. This definition is now not appropriate, since many alternative
remedies have recently found their way into the medical mainstream. Medical schools
teach alternative medicine, hospitals and health maintenance organizations offer it, and
laws in some states require health plans to cover it. A more state-of-the-art definition is
the diagnosis, treatment and/or prevention, which complements mainstream medicine by
contributing to a common whole, by satisfying a demand not met by traditional medicine
or by diversifying the conceptual framework of medicine (Angell & Kassirer, 1998). The
National Center for Complementary and Alternative Medicine (NCCAM) of the National
Institutes of Health (NIH) has grouped the practice of alternative medicine into the
following five major domains: (1) alternative medical systems (traditional oriental
medicine including acupuncture, herbal medicine and oriental massage; ayurvedic
medicine that is India’s traditional system of medicine and includes diet, exercise,
meditation, herbs, massage, exposure to sunlight and controlled breathing; homeopathy
and naturopathy), (2) mind-body interventions (meditation, hypnosis, dance, music and
art therapy, prayer and mental healing), (3) biological-based therapies (herbal, special

dietary, orthomolecular, and individual biological therapies including use of shark
cartilage), (4) manipulative and body-based methods (chiropractors, osteopathic
manipulation and massage therapists), and (5) energy therapies (biofield therapies and
bioelectromagnetic-based therapies) (http://nccam.nih.gov/nccam/fcp/classify/) (appendix
i).
The practice of alternative medicine has gained popularity among patients and the
general population. The annual prevalence of Complementary and Alternative Medicine
(CAM) use in the U.S.A is 40%, in Australia 50% and in Germany 65% (Ernst and
Cassileth, 1999). Many factors may be driving this popularity, such as a rise in chronic
diseases, greater access to health information, increased demand for improved quality of
life, and the desire for more effective and less toxic therapies (Marcus et al., 1999). In
1992, Congress established within the NIH an Office of Alternative Medicine with the
purpose of evaluating the efficacy and safety of alternative remedies. More recently, in
1998, the Congress elevated the NIH Office of Alternative Medicine to the National
Center for Complementary and Alternative Medicine (NCCAM) at the NIH. In 1999, the
Center had a budget of $50 million, which was increased in 2000 to $68.7 million. The
reason for Congress’s growing interest in CAM is the estimated 83 million adults who
used at least one form of alternative medical therapy in 1997, compared with 60 million
adults in 1990 (Eisenberg et al., 1998). There is a great demand by the public and
scientific community that CAM studies be carried out, which provide scientifically
reliable evidence of safety and efficacy following rigorous testing, similar to that required
by the Food and Drug Administration (FDA). That is, they must be subjected to the same
level of scrutiny required for the approval of drugs and that result of studies be published

in reputable peer-reviewed journals. The latter is a mission of the newly created NCCAM
(Muscat, 1999). An increasing number of publications in scientific journals are devoted
to alternative medicine, particularly in the area of cancer research, where there are a large
number of studies involving CAM, probably because of the widespread use of alternative
regimens by cancer patients. (Ernst and Cassileth, 1999) Unfortunately, such therapies
can prove harmful in some patients by delaying needed mainstream treatment, or cause
undesirable physiological problems if they have unexpected effects on the recipient.
One form of CAM, which is gaining considerable popularity is the oral use of
shark cartilage, not only as a therapeutic agent, particularly in case of cancer, but also as
a prophylactic measure. The interest in shark cartilage stemmed from early studies
carried out by Folkman (1971). Initial interest in cartilage as an inhibitor of angiogenesis
came from its unique physical characteristic of being a tissue lacking nerves or blood
vessels. The absence of blood vessels prompted several researchers to investigate
cartilage as a possible source of inhibitors of angiogenesis (Langer et al., 1976). The
rationale being that by limiting or inhibiting blood vessels to developing tumors their
growth and/or survival could be controlled. Studies have found that cartilage contains
more naturally occurring factors that inhibit angiogenesis than molecules that activate
angiogenesis, which may well account for the absence of blood vessels in cartilage
(Langer et al., 1976).
During the early seventies, Folkman (1971) originally proposed that solid tumors
could not grow beyond the size of 1-2 mm without inducing the formation of new blood
vessels to supply the nutritional needs of the tumor, and he suggested that this
neovascularization might be a novel target for cancer therapy. The development of a new

vascular network from a pre-existing vessel is called angiogenesis and occurs in
physiological states such as embryonic development, menstrual cycle and wound healing,
where it is necessary to continuously supply the tissue with oxygen and nutrients as well
as for removal of waste products. However, excessive angiogenesis is part of the
pathology of several non-related diseases. Among these diseases are cancer,
atherosclerosis, rheumatoid arthritis, psoriasis, endometriosis and diabetic retinopathy
(Griffioen and Molema, 2000). In case of cancer, tumor cells secrete angiogenic proteins,
such as vascular endothelial growth factor (VEGF), which binds to specific receptor on
the endothelial cells lining the blood vessels (Griffioen et al., 1998). When these cells are
activated by angiogenic signals, the process of forming a new blood vessel is initiated
with the production of enzymes called matrix metalloproteinases (MMPs). MMPs create
an opening in the blood vessel wall and break down the surrounding tissue to clear a path
for endothelial cells to move toward the source of the angiogenic signals. The endothelial
cells then divide and eventually strands of new endothelial cells organize into hollow
tubes creating a new network of blood vessels, thereby, connecting the tumor to a
network of existing blood vessels (Griffioen et al., 1998). Based on these observations,
investigators believed that the inhibition of angiogenesis might offer a new and powerful
approach to cancer treatment, either alone or in combination with conventional therapies.
This approach may also benefit other chronic diseases where undesirable angiogenesis is
involved. In the case of chronic inflammatory diseases, including rheumatoid arthritis and
psoriasis, neovascularization is a proeminent feature. Angiogenesis is believed to be
required for the pannus formation, which is the characteristic change in the synovial
architecture in rheumatoid arthritis and psoriasis (Jackson et al., 1997; Storgard et a l,

1999). This neovascularization not only maintains the chronic architectural changes via
delivery of required blood-borne elements to the pannus, but also to play an active role in
the inflammation by being a source of inflammatory cytokines, chemokines, and
proteases. Many cell types are capable of producing angiogenic factors when their
enviroment becomes inflammatory, such as tumor cells, keratinocytes, corneal
fibroblasts,

synovial

fibroblasts,

monocytes

and macrophages.

Monocytes

and

macrophages can be found at most sites where angiogenesis is occurring in abnormal
enviroment and they can produce almost every growth factor and cytokine known to
regulate angiogenesis (Jackson et al., 1997). Currently, investigators are using four
strategies to design anti-angiogenesis agents: 1) block the MMPs, 2) directly inhibit
normal endothelial cell proliferation, 3) block factors that stimulate angiogenesis, and 4)
block the action of integrin, a molecule on the endothelial cell surface that binds the
endothelial cell with the extracellular matrix (Griffioen and Molema, 2000).
Brem and Folkman (1975) were the first to demonstrate the antiangiogenesis
property of mammalian cartilage on tumor development. When cartilage obtained from
neonatal rabbits was implanted with V2 carcinoma cells into rabbit cornea or the
chorioallantoic membrane of chick embryo, tumor inhibition was noted. Based on these
results, Lee and Langer (1983) undertook search for this vascular inhibitor in sharks,
which unlike mammals, have an endoskeleton composed entirely of cartilage that
represents approximately 6% of their total body weight. Shark cartilage extract was
incorporated into polymer pellets and implanted into the cornea of New Zealand white
rabbits, together with V2 carcinoma tumors. They found that a crude extract of shark
cartilage prepared by extraction with a solution containing 1M guanidine and 0.02M 2-

(N-morpholino) ethanesulfonic acid (MES) for 41 days at room temperature strongly
inhibited tumor neovascularization and that the inhibitor did not appear to act directly on
the tumor itself, but rather on capillary advancement towards the tumor. Subsequently,
Prudden (1985) reported on clinical cases in which patients were treated with a specific
preparation of bovine cartilage called Catrix. Thirty one cancer patients showed a high
response rate of 90% over extended periods of treatment. Prudden suggested that Catrix
has the capacity to arrest the growth of many types of tumors, but not to eliminate them
completely.

Several

investigators

further

studied

the

antitumor

activity

and

immunoregulatory effects of Catrix (Romano et al., 1985; Durie et al., 1985; Rosen et al.,
1988). Generally, they found that Catrix has antitumor activity demonstrating inhibition
of tumor growth, and an immunostimulatory activity with enhancement of antibody
response. The substance in Catrix that induces the immunomodulatory effects appeared to
be related to chondroitin sulfate, based on similar effects observed in vivo with that
shown previously with chondroitin sulfates C and A and also the sensitivity of Catrix to
digestion with chondroitinase ABC, an enzyme with specificity for chondroitin sulfates
and related glycosaminoglycans.
Moses et al. (1990) were the first to isolate a protein derived from bovine
cartilage that inhibited angiogenesis in vivo, and capillary endothelial cell proliferation
and migration in vitro. They also found that the angiogenesis inhibitor is also a
collagenase inhibitor. Since these earlier studies, other investigators have demonstrated
the antiangiogenic activity of shark cartilage, and have isolated the antiangiogenesis
component from shark cartilage (Oikawa et al., 1990; Sheu et al., 1998). Oikawa et al.
(1990) conducted a study to evaluate the inhibitory activities of crude fractions of

Japanese shark cartilage. They analyzed the angiogenic response of rabbit cornea
following implantation of rabbit VX-2 carcinoma, and embryonic angiogenesis in chick
embryo chorioallantoic membranes (CAM) in the presence and absence of shark cartilage
fractions. They demonstrated inhibitory activities of crude fractions in the two assays
performed, mainly with fractions of molecular weight between 1,000 and 10,000 Daltons,
and that this inhibitory activity was resistant to heat treatment (2 hours at 37°C or 3
minutes at 100°C). More recently, a potent angiogenesis inhibitor, U-995, was purified
from blue shark cartilage (Sheu et al., 1998). The study found that U-995 is composed of
two single peptides with molecular mass of 10 and 14 kDa, which inhibit endothelial cell
proliferation and migration, and inhibition of collagenolysis leading to inhibition of both
angiogenesis and tumor cell growth.
Sharks have inhabited the oceans for many millions of years and are noted to be
naturally resilient to disease and trauma (Pettit and Ode, 1977). Because of their
impressive survival record and since their skeleton is composed entirely of cartilage
(which is believed to contain anti-angiogenic factors) they have become a focus of study
of investigators in cancer research (Prieur et al., 1976; Lee and Langer, 1983; Mathews,
1992). Shark cartilage therapy has been widely used for the treatment of a variety of
illnesses (such as, rheumatoid arthritis and other auto-immune diseases, psoriasis,
scleroderma, AIDS, various forms of cancer), as an anti-inflammatory agent, in wound
healing and for prophylactic purposes as a preventive measure against disease. During the
Chantilly conference, which was sponsored by the NIH on alternative therapies,
investigators reported that about 50,000 Americans were using shark cartilage at an
annual cost of about $7,000 or more, and that these numbers were expected to increase

through the following years (Workshop on Alternative Medicine. Washington, DC: US
Government Printing Office; 1992). However, the effectiveness of shark cartilage for the
treatment of human disease is still very controversial (Blackadar, 1993; Markman, 1996;
Ernst, 1998). Comprehensive data, including reliable dose-response data, are still
unavailable (Ernst, 1998). There is no convincing evidence that shark cartilage offers any
therapeutic or prophylactic benefit. It is possible that it might be harmful when taken
during certain disease states, such as chronic inflammatory diseases.
Patients suffering from malignant, chronic and/or degenerative diseases as well as
healthy people are taking shark cartilage for therapeutic and prophylactic purposes, and
the use of shark cartilage is increasing. This observation disturbs some investigators, who
are concerned that the increasing demand for shark cartilage will endanger the survival of
shark species. Shark populations are diminishing, especially in the Gulf of Mexico, and
much of this depletion is the result of years of unregulated killing of sharks for their fins
or by sport fishermen (Mathews, 1992; Campagno, 1999). Sharks are particularly
vulnerable because they have a relatively low reproductive capability, are slow to reach
sexual maturity, and have long reproductive cycles (Simpfendorfer, 1998). The demand
for shark cartilage as a therapeutic agent and prophylactic substance increases the
pressure on shark population, which are hunted to secure large amounts of cartilage for
commercial use. Sharks maintain an important relationship with the ocean environment,
not only by controlling fish overpopulation, but also by ridding the ocean of diseased or
injured fish, and their endangerment could result in major ecological problems (Mathews,
1992; Olsen, 1999; Tricas, 1999). Since the short and long-term effects of shark cartilage
are not known, the indiscriminating killing of sharks is presently not medically

justifiable. Nevertheless, a preparation of shark cartilage has been shown to play a
scavenger role for reactive oxygen species, thus, protecting cells against hydrogen
peroxide-induced damage and mutagenesis, which are processes involved in the
pathogenesis of several degenerative diseases (Gomes et al., 1996; Felzenszwalb et al.,
1998).
There are very few publications showing the effects of cartilage on the immune
system. Rosen et al. (1988) found that Catrix-S enhanced T-cell dependent and T-cell
independent antibody responses in mice, in a dose-dependent manner, and that this
immunomodulatory effect appeared to be related to chondroitin sulfate present in Catrix.
Fontenele et al. (1996) observed an anti-inflammatory and significant analgesic activity
of a water-soluble fraction (WSF) from shark cartilage. The experiments consisted of oral
administration of WSF from shark cartilage to rats one hour before the animals were
challenged with carrageenan and dextran to induce inflammation. The challenge
substances were injected in the paws of the test animals and the inhibition of edema was
evaluated. Furthermore, during the same study, mice were treated orally with WSF from
shark cartilage one hour before they were injected intraperitoneally with acetic acid to
evaluate the analgesic response, by observing significant reduction in the number of
writhings after treatment in test animals compared to the untreated controls. They also
demonstrated that the effects noted are due to a peptide, and are nitric oxide systemdependent (Fontenele et al., 1997).
More recently, Chen et al. (2000) have investigated the effects of shark cartilage
extract on endothelial cell attachment and spreading properties. Cell-substratum adhesion
is a critical step during cell growth, development, differentiation, and cancer metastasis.

The adhesion process is mediated by the formation of focal adhesions (FAs), which
involves the binding of cell surface receptor integrins to the extracellular matrix via their
extracellular domains (Hynes, 1992). It was found that shark cartilage extract both
induces cell detachment by reorganization of FAs and stress fibers, and interferes with
cell attachment and spreading by decreasing FA formation and preventing stress fiber
formation.
The role of shark cartilage as a potential cancer treatment became very
controversial when certain investigators questioned the effectiveness of it on tumors,
mainly because they doubted whether the proteins responsible for the antiangiogenic
activity reach the blood stream, since shark cartilage preparations are taken orally and are
composed primarily of macromolecules, which normally are too large to be absorbed by
the intestinal tract. Scientists were critical of the lack of reliable dose-response data,
bioavailability studies, and the presence of binding agents and fillers in the cartilage
preparations, which do not have any antiangiogenic activity (Mathews, 1993; Blackadar,
1993; Markman, 1996; Ernst, 1998; Simone et a l, 1998). Several investigators have
reported on the absorption of intact macromolecules by the intestinal tract after their oral
ingestion (Warshaw et a l, 1974; Gardner, 1988). In an initial study (Baici et al., 1992),
the bioavailability of oral chondroitin sulfate, the major glycosaminoglycan present in
cartilage, was investigated. It was shown that chondroitin sulfate, derived from oral
administration is not absorbed as an intact molecule from the mammalian digestive tract.
However, dermatan sulfate, another glycosaminoglycan of relatively large molecular
weight, was shown to be absorbed after oral administration and a wide range of

molecular weight (from 7,500 to 20,000 Daltons) of different compounds reached the
blood stream (Volpi, 1996).
The inhibition of angiogenesis following oral ingestion of shark cartilage has been
studied. A rat model was used to demonstrate for the first time that oral administration of
powdered shark cartilage has a potent inhibitory effect on angiogenesis (Davis et al.,
1997). Rats were fed with ground rat food, supplemented or not with shark cartilage, two
weeks prior to the induction of angiogenesis in the avascular mesenteric window with the
compound 48/80 twice daily for 4.5 days. The mesenteric windows were surgically
removed and a positive reduction of angiogenesis was shown by light microscopy. In
humans, the bioavailability of the antiangiogenic component was demonstrated after the
oral administration of a liquid cartilage extract to healthy males (Berbari et al., 1999).
This was a prospective study, randomized, controlled, double-blind trial using 29 healthy
volunteers. Subjects were randomized into three groups, and each ingested placebo and
two different doses of shark cartilage extract on a daily basis for 23 days. On the twelfth
day, an inert polyvinyl alcohol ((PVA) sponge implant was inserted subcutaneously into
the left arm and removed on the 23rd day. After the implant was removed, it was divided
in three parts for analysis as an indirect measurement of angiogenesis. The middle portion
was preserved in formalin and used for the measurement of endothelial cell density using
monoclonal antibody staining. The other two portions were used for hydroxyproline
(marker of collagen deposition) and total protein measurement. Evaluation of the PVA
implant sections showed a significant reduction of endothelial cell density in groups that
were administered the liquid cartilage extract. The authors concluded that their study is
the first to provide evidence of the bioavailability of the cartilage-derived antiangiogenic

factor after oral administration in humans. It should be noted, however, that the migration
of endothelial cells might be the indirect result of factors induced by cartilage rather than
the direct effect of a component of shark cartilage.
The use of shark cartilage in other disease states such as psoriasis and rheumatoid
arthritis has been also evaluated. Dupont et al. (1998) investigated angiogenesis
inhibition by extracts of shark cartilage. They tested an active agent, termed JE-941, for
angiogenesis activity using the embryonic vascularization test (a modified CAM), for
collagenase activity using a fluorogenic peptide substrate, and last for anti-inflammatory
properties using a cutaneous irritation model in humans. Based on their results they
suggested that jE-941 has anti-angiogenic and anti-inflammatory properties. However,
there are discrepancies in the results from different studies and, to date, no controlled
clinical trials have been undertaken to assess its effect (Henderson et al., 1999; Deal et
al., 1999).
In a recent study (Morris et al., 2000), the effect of therapeutic potential of boron
neutron capture therapy, a cancer therapy, in combination with the oral administration of
shark cartilage was evaluated. Rats received intracranial tumor implantation and were
irradiated with boron neutron capture therapy with or without simultaneous treatment of
an aqueous suspension of shark cartilage. The study concluded that shark cartilage alone
significantly increased the survival time of tumor-bearing rats owing to its antiangiogenic
effect; however, boron neutron capture therapy was not enhanced by the combination
with shark cartilage. In 1998, a phase I/II clinical trial was launched to evaluate the safety
and efficacy of shark cartilage treatment of patients in advanced stage of cancer and who
had previously been treated, or had recurrent and/or metastatic cancer of the lungs,

breasts, colorectum, prostate, bladder, brain or non-Hodgkin’s lymphoma (Miller et al.,
1998). This was an open label, non-randomized study that involved 60 adult patients with
advanced (stage III to IV) cancer, who were treated with shark cartilage for 12 weeks.
Patients of the study were not on conventional anticancer therapy at the time of the trial,
and had previously not used shark cartilage. The results of the study showed no toxic
effect of shark cartilage in most patients (measured by hematological, biochemical and
immunological parameters) and mild adverse effects primarily from gastrointestinal
origin. However, no significant anticancer activity was noted in these patients. Between
the end of 1996 and 1998, phase I/II clinical trials were developed in Canada using a
liquid extract from shark cartilage called JE-941/Neovastat (Sterna Laboratories). These
studies included 186 refractory lung and prostate cancer patients, 142 refractory solid
tumor patients, 49 psoriasis patients and 10 macular degeneration patients. The extract
was administered orally by itself, or in combination with either chemotherapy or
radiotherapy on a daily basis for a minimum duration of 3 months or lasting for more
than 3 years in some cases. The investigators suggested that results fron the study were
positive and the clinical results indicated that JE-941/Neovastat has an excellent safety
and tolerability profile (appendix ii). A phase III clinical trial is undergoing in Canada
and the United States using the same preparation. This is a randomized study in which
cancer patients are administered Neovastat in combination with chemotherapy drugs and
radiation treatment to test the effectiveness of the extract in increasing patient survival.
The control group receives in place of Neovastat a corresponding amount of placebo. All
patients receive standard chemotherapy followed by radiation treatment in combination
with the chemotherapy (Neovastat, Aetema Laboratories, Quebec, Canada). At this

moment, the oral administration of shark cartilage has more often been evaluated as a
complementary therapy, in combination with conventional therapies, which is more
reasonable believing that cartilage does not have any direct effect on tumor cells, but
rather inhibits angiogenesis that limits tumor growth and metastasis.
An important facet of shark cartilage administration, which has not been
addressed comprehensively by investigators, is the effect of shark cartilage on normal
immune function, particularly when taken long term. A systematic study to determine its
affect on various cell types, their cytokine response, phagocytic and chemotactic ability,
proliferative and apoptotic response has not been carried out.
Tumor necrosis factor- alpha (TNF-a) is a key mediator of inflammation and is
produced by the mammalian host in response to injury or invasion by microbes, parasites
or neoplasia. TNF-a is a cytokine produced by many cell types after appropriate
stimulation. The monocytes/macrophages are the major source when stimulated mainly
with lipopolysaccarides (LPS) and phorbol diesters. Mast cells and neutrophils also
produce TNF-a in response to LPS stimulation. Other hematopoietic cells of lymphocytic
origin, such as T-cells, B-cells and natural killer (NK) cells, also produce TNF-a in
response to stimulation with phorbol diesters, phytohemagglutinin and concanavalin A,
but not in response to LPS (Sidhu and Bollon, 1993). The biological effects of TNF-a
include cytotoxicity through antiproliferative effect and induction of necrotic or apoptotic
cell death, differentiation of many cell types, growth stimulation of a number of normal
and tumor cells, antiviral activity through lysis of viral infected cells, immunomodulatory
and pro-inflammatory activity, gene induction and killing of tumor cells (Beyaert and

Fiers, 1998). The antitumor activity of TNF-a in vivo depends primarily on the ability of
TNF-a to cause vascular changes in the tumor causing a hemorrhagic necrosis of the
tumor. The hemorrhagic necrosis might be caused by direct toxic effect and activation of
procoagulant activity in tumor endothelium, and by activating antitumor immune
response of host cells, activating macrophages, cytotoxic T-cells, natural killer cells and
neutrophils. The antitumor effect can be further enhanced by other cytokines, such as
interleukin-1 (IL-1) and IL-6, induced by TNF-a (Sidhu and Bollon, 1993; Beyaert and
Fiers, 1998). However, in case of overreaction of the host or deficiency of a natural
autoregulatory network, TNF-a has several potent deleterious effects and is implicated as
a mediator of acute and chronic autoimmune diseases and inflammatory conditions
(Beyaert and Fiers, 1998). In the case of rheumatoid arthritis, TNF-a is often present at
the site of inflammation and when it is blocked with anti- TNF-a antibody, down
regulation of several pro-inflammatory agents occurs leading to local beneficial effects
(Feldmann and Maini, 1999). Patients with active psoriasis often have increased TNF-a
and IL-6 levels in the psoriatic plaques, and even in the plasma.
TNF-a and shark cartilage have independently, a direct antiproliferative effect in
endothelial cells. When shark cartilage and TNF-a are added to a cell culture to stimulate
endothelial cells in vitro, a synergic effect is observed in reducing cell proliferation
measured by 3H-thymidine incorporation by human umbilical vein endothelial cells
(HUVEC) (McGuire et al., 1996). The production of TNF-a by endothelial cells
stimulated with shark cartilage, or the synergic effect of shark cartilage combined with
TNF-a, may play a role in regression of growing tumors and remission of other

degenerative diseases, through a direct effect of both substances on angiogenesis by
inhibiting endothelial cell proliferation. An earlier study carried out in our laboratory
showed that shark cartilage extracts (acid, salt-soluble and phosphate-buffered saline
extracts), prepared from commercial sources of shark cartilage, stimulated human
leukocytes in vitro to release significant levels of TNF-a, which could be detected in cell
culture supernatants by ELISA (Simjee, 1997; Simjee and Smith, 1997). The highest
TNF-a response was obtained with the acid extract. It is not known what other cytokines
are induced in vitro by shark cartilage and whether the response is associated with the
activation of any particular cell type.
TNF-a is a cytokine typically produced in vivo during T helper-1 cellular (Th-1)
response, i.e. an inflammatory response. Helper T cells can be classified in two subsets,
Th-1 and Th-2, based on their pattern of cytokine synthesis when stimulated by antigens
(Gajewski et al., 1989). As cytokines are major determinants of the functions of the T
cells that produce them, these patterns lead to different properties of the T cell subsets.
Th-1 cells mediate several functions involved in cytotoxicity and local inflammatory
reactions, therefore, being particularly effective at combating viruses and intracellular
bacteria and parasites (Mosmann and Coffman, 1989). In general, a strong Th-1 response
in the absence of any Th-2 response might be expected to result in delayed-type
hypersensitivity (DTH) with little or no antibody production. In contrast, a Th-2 response
leads to high general antibody levels, including the production of IgE and associated
eosinophilia, being more effective against extracellular bacteria and in inducing
protective humoral immunity. Antibody production and DTH reactions are often
mutually exclusive during immune responses in mice, and this can be partially explained

by cross-inhibition of Th-1 and Th-2 cells (Street and Mosmann, 1991). Although
strongly biased Th-1 or Th-2 responses would be expected to result in clearly
distinguishable immune responses, many normal responses in humans may involve a
mixture of the two types of cells. The isotype patterns may depend on the ratio of Th-1
and Th-2 activation (Mosmann and Coffman, 1989; Swain et al., 1991). In case of
cytokine induction by shark cartilage, it is important to identify the factors being induced,
since the pattern of induction reflects the type of cells responding, which in turn will
determine the potential use or harm to the host.
IL-4 plays an important biological role as it modulates cytokine production by T
cells, B cells and NK cells, monocytes/macrophages, endothelial cells and fibroblasts
(Banchereau and Rybak, 1994). Unlike TNF-a, IL-4 is a cytokine that is typically
secreted in vivo during a Th-2 cellular response, i.e. an anti-inflammatory response. IL-4
which is involved in the differentiation of Th-2 cells, originates from basophils/mast cells
while interferon gama (IFN-y) and IL-2, which induce the maturation of Th-1 cells
originate from NK cells and macrophages, respectively. An important feature of Th-1 and
Th-2 cells is the ability of one subset to regulate the activities of the other. It occurs at the
level of the effector cells that are triggered by these subsets, as indicated by the inhibitory
effects of IFN-y on IL-4-induced B cell activation or those of IL-4 on IL-2 induced T and
B lymphocyte proliferation (Banchereau and Rybak, 1994). In a study carried out by
Abehsira-Amar et al. (1992), they demonstrated that IL-4 positively controls the
differentiation of Th-0 into Th-2 cells and negatively controls the differentiation of Th-0
into Th-1 cells. They neutralized secreted IL-4 with anti-IL-4 monoclonal antibody and
completely prevented the differentiation of Th-0 into Th-2 cells, but permitted the

development of Th-1 cells. Based on their results, they suggested that IL-4 is the
principal factor that controls the differential development of Th-0 cells into Th-1 and Th2 cells. In vivo studies have also demonstrated an important anti-tumor effect for IL-4,
and its recombinant form is well tolerated by advanced cancer patients (Redmond et al.,
1992; Banchereau and Rybak, 1994). In addition to its potential use in the treatment of
cancer, IL-4 may be an effective agent in the treatment of a variety of diseases due to its
immunomodulatory and anti-inflammatory properties. In particular, the inhibitory effects
of IL-4 on the in vivo and in vitro production of cytokines, such as IFN-y and IL-2,
provide a strong rationale for its use in chronic inflammatory diseases such as rheumatoid
arthritis or other inflammatory diseases where an excess of Th-1 activity is observed. IL4 thus can equilibrate the balance between Th-1 and Th-2 cellular response (AbehsiraAmar et al., 1992, Banchereau and Rybak, 1994).
The present study in addition to examine cytokine response, will also examine
another important biological phenomenon, that is, apoptosis. The induction of apoptosis
of human leukocytes by shark cartilage extract will be investigated. The biochemical
hallmark of apoptosis is the intemucleosomal fragmentation of genomic DNA, producing
fragments that are multiples of approximately 185 bp. These fragments can readily be
demonstrated by agarose gel electrophoresis of DNA isolated from apoptotic cells, which
appear as a typical ladder pattern (Arends et al., 1990). Apoptosis is also characterized
morphologically by a series of typical events, such as shrinkage of the cell and the
nucleus as well as condensation of nuclear chromatin into sharply delineated masses that
become marginated against the nuclear membrane. The nucleus condenses progressively,
the cell detaches from the surrounding tissue and its outline becomes convoluted to form

extensions that separate and seal the plasma membrane forming the apoptotic bodies
(Saraste & Pulkki, 2000). All these morphological changes can be readily detected by
light microscopy. Apoptosis occurs under physiological conditions in normal cells to
maintain homeostatic regulation of normal tissue. Apoptotic deletion of lymphocytes
serves important normal function in the immune system. Immature thymocytes have been
shown to undergo apoptosis when stimulated via T-cell receptor at a critical stage in their
maturation, and it is the mechanism responsible for elimination of autoreactive T-cell
clones during development of cellular immune self-tolerance (Tomei and Cope, 1991;
Saraste & Pulkki, 2000). The loss of normal apoptosis is an important aspect of tumor
progression. Tumor cells have to acquire the ability to resist apoptosis in order to
progress. The lost of normal balance between mitosis and apoptosis leads to tumor
development. Apoptosis is crucial to maintain normal cell function. Cells that have
important DNA mutations, which cannot be repaired, undergo apoptosis. Senescent cells
and aging neutrophils are eliminated by apoptosis (Lundberg & Weinberg, 1999).
Because this biological function is a crucial aspect of the normal cell cycle, this study
plans to evaluate the effect of shark cartilage on apoptosis of human leukocytes.
Shark cartilage therapy is widely used for the treatment of a variety of disease
states and for prophylaxis. In the latter case, healthy people are taking it indiscriminately
without knowing the short and long-term effects of this substance. Shark cartilage
preparations are easily available from drugstores and health food stores where they are
sold as a food supplement and do not require FDA approval. The effectiveness of shark
cartilage as a treatment for a variety of human disease is still very controversial, mostly
because complete and reliable dose-response data is unavailable. At present, there is no

evidence that shark cartilage offers any benefit for the treatment of human disease or as a
prophylactic agent. In fact, preliminary studies indicate that it is possible that shark
cartilage might cause harm if taken during certain disease states, such as inflammatory
chronic diseases, where undesirable immune response may be up regulated. TNF-a and
IL-4 are cytokines that are characteristic of two different types of immune responses, Th1 and Th-2 respectively. The first is associated with inflammation, while the latter is
typically produced in anti-inflammatory responses along with the production of
antibodies. The two are believed to be mutually exclusive (Mosmann and Coffman,
1989). Previous in vitro studies have shown that shark cartilage induces human
leukocytes to produce TNF-a, a cytokine that, in vivo, characterize a Th-1 response
(Simjee and Smith, 1997).
Based on these observations, it is necessary to investigate further the effect of
shark cartilage on components of the human immune system initially through in vitro
studies, followed by in vivo evaluation to determine the long term consequences of its
administration on human disease and on the health of normal individuals. The main focus
of the proposed study is to examine the types of in vitro cellular responses induced by
shark cartilage. The study will determine whether shark cartilage will induce cells to
produce IL-4, a Th-2 type cytokine. Furthermore, in addition to TNF-a, a cytokine
characteristic of Th-1 type response, the study will also examine the effect of shark
cartilage on in vitro production of IFN-y by stimulated cells. Since tumor development
results from uncontrolled proliferation of affected cells by their loss of the normal cell
apoptotic machinery, this study will also examine the influence of shark cartilage on
apoptosis of normal competent immune cells. Similarly, cell proliferation, too, will be

assessed following treatment with and/or in the presence of shark cartilage. The study
will also attempt to distinguish the degree of responsiveness to shark cartilage by
different cell types by using specific cell-enriched fractions of leukocytes to set up cell
cultures.

M a te ria l and M eth o d s
Blood Donors
Consent forms from all human subjects who donated blood to be used during this
study are present in appendix iii.

Chemical and Reagents
All chemicals and reagents used in this study are listed in appendix iv.

Sterilization
All solutions, tubes and glass containers used throughout the study were sterilized
by autoclaving at 121°C, 15 psi for 15 minutes or filter sterilized through 0.45 pm
Nalgene filters.

Cell Culture Medium
Human peripheral blood leukocytes were cultured in RPMI-1640 medium (Life
Technologies, Inc., Rockville, MD), supplemented with 300 mg/ml glutamine, 25 mM
HEPES, 10 % heat-inactivated newborn calf serum (Life Technologies, Inc., Rockville,
MD), 100 U/ml penicillin and 100 pg/ml streptomycin (Life Technologies, Inc.,
Rockville, MD). Medium was filter sterilized.

Shark Cartilage Extract
Acid extract of shark cartilage (ASC) was prepared from commercially available
shark cartilage capsules marketed as Cartilade (Solgar Laboratory, Leonia, NJ). Three
grams of shark cartilage were dissolved in 50 ml of 0.5 M acetic acid containing 0.03%
toluene, pH 4.2 and incubated overnight at 4°C with continuous stirring. The preparation

was centrifuged at 900 x g for 10 minutes at 4°C, the insoluble precipitated material was
discarded and the supernatant filtered through a 0.45 pm filter, followed by filtration
through a 0.22 pm filter (Coming Costar Corp., Cambridge, MA) using a needle and
syringe. Initially, the filtered extract was dialyzed overnight at 4°C, using a Slide-ALyser Cassette (Pierce Chemical Co., Rockford, IL) with a molecular cut off of 3,500
kDa, against Tris 0.02M, pH 7.4. The dialyzed samples were filtered a final time through
a 0.22 pm filter and stored at —20°C. Total protein concentration was determined for the
dialyzed, filter-sterilized extract. Before use in cell culture extract preparations were
dialyzed for 4 hours at 4°C against RPMI-1640 supplemented with glutamine and
HEPES. Furthermore, each extract preparation was tested for endotoxin using the EToxate kit before it was used as a stimulant in the cell cultures.

Protein Determination
Determination of total protein concentration of the acid shark cartilage extract
was performed using the BCA-Protein assay (Pierce Chemical Co., Rockford, IL)
according to the manufacture’s recommended protocol. Briefly, 0.1 ml of the acid shark
extract sample and of each concentration of the BSA standards provided in the kit were
individually mixed with 2.0 ml of working the reagent, prepared by mixing 50 parts of
reagent A (sodium carbonate, bicarbonate, and sodium tartarate in 0.1 N NaOH) with one
part of reagent B (4% copper sulfate solution). The mixture was incubated at 37°C for 30
minutes. After incubation, samples were allowed to cool to room temperature and the
absorbance of each test sample and control standards was measured at 562 nm using an
Ultrospec 3000 spectrophotometer (Pharmacia Biotech Inc., Alameda, CA). Plotting the
optical density readings of each standard against its corresponding concentration

generated a standard curve, which was used to determine the protein concentration in
pg/ml of the cartilage extract from its optical density. The concentrations of BSA
standards used to prepare the standard curve were 100 pg/ml, 200 pg/ml, 400 pg/ml, 600
pg/ml, 800 pg/ml and 1000 pg/ml.

Assay for Endotoxin
To detect and quantify the level of endotoxin in test reagents and samples, the EToxate test kit (Limulus Amebocyte Lysate Assay, Sigma Chemical Company, St. Louis,
MO) was used. The sensitivity of the test ranges from 0.05 to 0.1 endotoxin units (EU)
per ml. Briefly, 0.1 ml of each test sample was mixed with 0.1 ml of E-Toxate working
solution (dry concentrate from Limulus polyhemus reconstituted with endotoxin-free
water according to the manufacturer’s instruction), and incubated undisturbed at 37°C for
one hour. After incubation, the tubes were gently inverted 180 degrees to observe
evidence o f gelation. The formation of a hard gel, which permits complete inversion of
the tube without disruption of the gel, constitutes a positive test. All other forms or
degrees of gelation ranging from a soft gel to a clear fluid are considered negative.
Endotoxin standards (LPS of E. coli 055:B5) were used as positive controls in
concentrations of 0.5 EU/ml, 0.25 EU/ml, 0.125 EU/ml, 0.06 EU/ml, 0.03 EU/ml and
0.015 EU/ml. Endotoxin-free water was used as a negative control. Test samples were
also tested for the presence of E-Toxate inhibitor(s) by mixing 0.01 ml of 4 EU/ml
standard with 0.1 ml of sample and 0.1 ml of E-Toxate working solution. The formation
of a hard gel indicates the absence of an inhibitor in the test sample.

Figure 1: Summary of protocols used during experimental work

Isolation of Human Peripheral Blood Leukocytes
Protocols employed for the isolation of leukocytes follows below. A flow chart
summarizing the experimental approach taken in this study is outlined in figure 1.

Protocol A
This protocol was followed to isolate a heterogeneous population of leukocytes
(PBL) from whole blood. Freshly drawn heparinized human blood (containing 20 U
heparin/ml whole blood) was mixed with an equal volume of 3% Dextran (MW 500,000,
Sigma Chemical Company, St. Louis, MO) in sterile physiological saline (0.15 M NaCl).
Red blood cells (RBC) were allowed to settle by gravity at room temperature for 30
minutes. The cloudy supernatant containing leukocytes was harvested and transferred to a
15 ml polypropylene plastic tube (Coming Costar Corporation, Cambridge, MA), and
then centrifuged at 400 x g for 10 minutes at 4°C. The supernatant was discarded and the
cell pellet gently resuspended in 7 ml of 0.2% NaCl for 30 seconds to lyse residual
contaminating RBCs. Immediately following RBC lysis, 7 ml of 1.6% NaCl (equal
volume to 0.2% solution used) was added to the cell suspension to bring the suspension
to physiological isotonicity (0.85% NaCl concentration) for human leukocytes. The cell
suspension was centrifuged at 400 x g for 10 minutes at 4°C. The RBC lysing procedure
was repeated once more, the supernatant discarded and the cell pellet washed once using
RPMI-1640 medium. Cells were resuspended in 12 ml of RPMI-1640 medium and a
manual cell count was performed using a hemacytometer. The volume of the cell
suspension was adjusted to give a final concentration of 1.2-1.3 x 106 cells/ml. Isolated
leukocytes were used immediately to set up cell cultures.

Protocol B
This protocol was employed to isolate a mononuclear cell-enriched fraction
(PBMC) of leukocytes. Freshly drawn heparinized human blood (containing 20 U
heparin/ml of heparin) was layered onto the surface of an equal volume of Histopaque1077 (Sigma Chemical Company, St. Louis, MO) and centrifuged at 400 x g for 30
minutes at 20°C, with the centrifuge break off. The PBMC-rich interface band, located
between the gradient mix and the plasma, was aspirated with a Pasteur pipette and
transferred into a clean 15 ml polypropylene plastic tube. Sterile physiological saline was
added to the cell suspension and the suspension centrifuged at 400 x g for 10 minutes at
4°C. The supernatant was discarded and the cell pellet was washed once more with
RPMI-1640 medium. Cells were resuspended in 6 ml of RPMI-1640 medium and a
manual cell count was performed using a hemacytometer. The volume of the cell
suspension was adjusted to contain 1.2-1.3 x 106 cells/ml and used immediately to set up
cell cultures.

Protocol C
This protocol was an alternative method to protocol B for the isolation of a
mononuclear cell-enriched fraction of leukocytes from whole blood. Freshly drawn
heparinized human blood was mixed with an equal volume of 3% Dextran in sterile
physiological saline (0.15 M NaCl). RBCs were allowed to settle by gravity at room
temperature for 30 minutes. The cloudy supernatant containing leukocytes was harvested
and transferred to a 15 ml polypropylene plastic tube, and then mixed with an equal
volume of physiological saline (0.15 M NaCl). The mixture was centrifuged at 400 x g
for 10 minutes at 4°C to remove the Dextran. The supernatant was discarded and the cell

pellet gently resuspended in 5 ml of physiological saline. The leukocyte-saline mixture
was layered onto the surface of an equal volume of Histopaque-1077 and centrifuged at
400 x g for 30 minutes at 20°C, with the centrifuge break off. The PBMC rich interface
band located between the gradient mix and the saline was aspirated with a Pasteur pipette
and transferred into a clean 15 ml polypropylene plastic tube. The cell suspension was
washed by the addition of 7 ml of sterile physiological saline and centrifuged (400 x g, 10
minutes at 4°C). The supernatant was discarded and cells were washed once more with
RPMI-1640 medium. The cell pellet was resuspended in 2 ml of RPMI-1640 medium and
a manual cell count was performed using a hemacytometer, and cell viability was
assessed using the trypan blue exclusion test.

Cell Viability
The cell viability of all standardized cell suspensions was determined by the
Trypan Blue exclusion test, which consists of mixing 0.1 ml of cell suspension with 0.1
ml of 0.4% Trypan Blue (Sigma Chemical Company, St. Louis, MO) in physiological
saline. Viability is confirmed by exclusion of the dye by cells. The percentage of viable
cells was calculated by loading a hemacytometer chamber with the dye-treated cell
suspension and counting 200 cells to determine the percentage of cells that excluded the
dye. The percentage of viable cells was calculated using the formula:
% viablecells = " ^ b e r o f cells excluding t h e d y e ^
total number o f cells counted
Only cell suspensions with a viability of 95% or higher were used to set up cell
cultures.

Leukocyte Cultures
In vitro leukocyte cultures were set up to study cell proliferation, apoptosis and
induction of cytokines. As culture conditions varied slightly depending on the purpose,
details are provided below.

Cell Proliferation
Leukocyte proliferation was measured directly by manual cell counts and
indirectly employing the MTT assay, which is based on the ability of living cells to
reduce

the
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(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl

tetrazolium bromide) to a purple-blue insoluble formazan precipitate, by dehydrogenase
activity present only in metabolically viable cells. PBMC fraction of leukocytes were
cultured in 24-well flat bottom tissue culture plates. Cell cultures were set up in duplicate.
Each well contained 200 pi of cell suspension (4 x 105 cells/well), 100 pi of growth
medium (RPMI-1640 supplemented with 300 mg/ml glutamine, 25 mM HEPES, 10 %
newborn calf serum, 100 U/ml penicillin and 100 pg/ml streptomycin) and 50 pi of the
test or control stimulant. The mitogens LPS (E. coli 026:B6, Sigma Chemical Company,
St. Louis, MO) and Concanavalin A (ConA, Sigma Chemical Company, St. Louis, MO)
were used at a concentration of 5pg/ml as positive controls and prepared in culture
medium (as above) without calf serum. The culture medium control was prepared by
replacing the sample with medium. Cell cultures were set up in duplicate as follows:
1. Test culture: 200 pi cell suspension + 100 pi medium + 50 pi ASC
2. Positive control culture: 200 pi cell suspension + 100 pi medium + 50 pi LPS
or Con A
3. Culture medium control: 200 pi cell suspension + 150 pi medium

The culture plates were incubated at 37°C for 4, 24 and 48 hours in a humidified
chamber with 5% CO2 . Following incubation, proliferation was assessed by manual cell
counts and the reduction of MTT. For manual cell counts, cells were harvested by gently
detaching cells attached to the bottom surface of the well by vigorous pipetting and
aspirating the content of each well with a pipette at 0, 4, 20, 24, 30 and 48 hours. A
hemacytometer chamber was loaded with the harvested cell suspension for cell count.

MTT Assay
In vitro cell proliferation was measured by the level of dehydrogenase activity in
metabolically viable cells following oxidative burst, which was determined by the MTT
assay. Following the incubation of cell cultures (as described above), 35 pi of a stock
solution of MTT (5 mg/ml in PBS 0.15 M, pH 7.2) was added to each well and cultures
were further incubated (37°C, 5% CO2 ) for 4 hours. To dissolve the insoluble formazan
crystals that form, 100 pi of 10% SDS in 0.02 M HC1 was added to all wells and the
mixtures incubated overnight at room temperature. Once the formazan crystals were
completely dissolved, the content of each well was transferred to a microcentrifuge tube
and centrifuged at 6,000 x g for 1 minute to remove all cell debris. The clear supernatants
(200 pi) were transferred to a 96-well microtiter plate and the absorbance read at 570 nm
in an ELISA reader (MRXII, Dynex Technologies Inc., Chantilly, VA), using a reference
filter of 630 nm. Absorbance is directly proportional to the level of dehydrogenase
activity associated with the oxidative burst, which in turn reflects the number of viable
cells present.

Leukocyte Culture for Cytokine Induction
Human PBL or PBMC fraction of leukocytes were cultured in 24-well flat bottom
tissue culture plates (Falcon, Becton Dickinson & Corp., Lincoln Park, NJ). Cell cultures
were set up in duplicate. Each well contained 200 pi of cell suspension (2.4 x 105
cells/well for PBL, and 2.2 x 105 cells/well or 1.36 x 106 cells/well for PBMC prepared
by Protocol B), 100 pi of growth medium (RPMI-1640 supplemented with 300 mg/ml
glutamine, 25 mM HEPES, 10 % newborn calf serum, 100 U/ml penicillin and 100 pg/ml
streptomycin) and 50 pi of test or control stimulant. Positive mitogen response controls
for B and T cell stimulation consisted of replacing the test stimulant with specific
mitogen. Five pg/ml of LPS (E. coli 026:B6, Sigma Chemical Company, St. Louis, MO)
was added to cultures to stimulate TNF-a and/or IFN-y production. In cultures set up for
IL-4 production, 5 pg/ml of Concanavalin A (ConA, Sigma Chemical Company, St.
Louis, MO) or 100 nM of phorbol 12-myristate 13-acetate (PMA, Life Technologies,
Inc., Rockville, MD) were used. The mitogen stock solutions were prepared in culture
medium described above without calf serum. Duplicate cell cultures were set up as
follows:
1. Test sample culture: 200 pi cell suspension + 100 pi medium + 50 pi ASC
2. Positive control culture: 200 pi cell suspension + 100 pi medium + 50 pi LPS
or Con A or PMA
3. Mitogen control culture: 300 pi medium + 50 pi LPS or Con A or PMA
4. Culture medium control: 200 pi cell suspension + 150 pi medium

The culture plates were incubated at 37°C for 4, 8, 20, 24, 30 and 48 hours in a
humidified chamber with 5% CO2 . At each specified time point, cells were harvested by
aspirating the contents of each well into a sterile microcentrifuge tube and centrifuging at
6,000 x g for 1 minute (Micromax RF, International Equipment Company, Needham
Heights, MA). Supernatants were collected and transferred to sterile microcentrifuge
tubes and stored at -80°C until assayed for TNF-a, IFN-y and/or IL-4.

Leukocyte Culture for Assessment of Apoptosis
Human PBMC fraction of leukocytes prepared by Protocol B were cultured in 24well flat bottom tissue culture plates. Cell cultures were set up in duplicate. Each well
contained 200 pi of cell suspension (1.5 x 106 cells/well), 100 pi of growth medium
(RPMI-1640 supplemented with 300 mg/ml glutamine, 25 mM HEPES, 10 % newborn
calf serum, 100 U/ml penicillin and 100 pg/ml streptomycin) and 50 pi of test stimulant.
Positive control cultures for apoptosis consisted of replacing the test stimulant with 5
pM/ml of staurosporine (Sigma Chemical Company, St. Louis, MO) or 5 pg/ml of
camptothecin (Sigma Chemical Company, St. Louis, MO), prepared as stock solution
initially in DMSO (Sigma Chemical Company, St. Louis, MO). A working solution of
apoptosis inducers was prepared in culture medium without calf serum. Duplicate cell
cultures were set up as follows:
1. Test sample culture: 200 pi cell suspension + 100 pi medium + 50 pi ASC
2. Apoptosis positive control culture: 200 pi cell suspension + 100 pi medium +
50 pi Staurosporine or Camptothecin
3. Culture medium control: 200 pi cell suspension + 150 pi medium

The culture plates were incubated at 37°C for 4 hours, 8 hours, 24 hours and 48
hours in a humidified chamber with 5% CO2 . At each specified time point, cells were
harvested by resuspending and aspirating the contents of each well into a sterile
microcentrifuge tube. The DNA from these cells was isolated using the Apoptotic DNA
Ladder kit according to the manufacturer’s instructions. The protocol is described later in
the isolation of leukocyte DNA.

Preparation of Leukocyte Cytospin monolayers
Cytospin films of PBL and PBMC (prepared according to Protocols A and B
respectively) were prepared for cytological examination of cell types in cultures, and for
cytochemical examination of cell types morphological changes characteristic of
apoptosis. Single cell layer films on glass slides were prepared by loading each cytospin
chamber (Cytopro, Wescor Inc., Logan, UT) with 0.2 ml of cell suspension aspirated
from cell cultures growing in 24 well cell culture plate. The chambers were placed in a
cytocentrifuge (Cytopro Centrifuge, Wescor Inc., Logan, UT) and cells centrifuged at 32
x g for 2 minutes onto microscopic slides coated with aminoalkylsilane (Silane-Prep
Slides, Sigma Chemical Company, St. Louis, MO). Slides coated with the leukocyte film
were air dried at room temperature for approximately 5 minutes, and stained with the
Hema 3 staining system (Fisher Scientific Co., Pittsburg, PA), an equivalent to WrightGiemsa staining. Slides were examined by light microscopy. For assessment of
morphological changes characteristic of apoptosis, 100 cells were counted on each slide
and the number of cells showing visible signs of apoptotic changes (listed below and
illustrated in Figure 2), as well as cells showing normal morphology were recorded.

Morphological assessment of apoptotic change was based on observing one or
more of the following morphological criteria for apoptotic cells:
Cell membrane convolutions (blebbing)
Cytoplasmic constriction with a reduction in cell volume;
Nuclei shrinkage, chromatin condensation and nuclear fragmentation;
Formation of apoptotic bodies

Assay for Extracellular Cytokine in Stimulated Cell Cultures
Cell cultures for cytokine production were set up using either PBL or PBMC
fraction of leukocytes. Cells were cultured in 24-well flat bottom tissue culture plates and
were set up in duplicate. Each well contained 200 pi of cell suspension (2.2 x 105
cells/well prepared by Protocol B), 100 pi of growth medium and 50 pi of test or control
stimulant. Positive control cultures for TNF-a production consisted of adding five pg/ml
of LPS to cultures. The culture plates were incubated at 37°C for 4, 8, 20, 24, 30 and 48
hours in a humidified chamber with 5% CO2 . At each specified time point, cells were
harvested by aspirating the contents of each well into a sterile microcentrifuge tube and
removing cell debris by centrifuging at 6,000 x g for 1 minute. Culture supernatants were
collected and transferred to sterile microcentrifuge tubes and stored at -80°C until
assayed for the presence of cytokines.

TNF-a Assay
A solid-phase enzyme-linked immunosorbent assay (ELISA) using monoclonal
antibodies against human TNF-a (Endogen Inc., Woburn, MA) was performed to detect
and quantitate the levels of TNF-a in cell culture supernatants. All reagents were
provided in the kit. Briefly, 50 pi of test sample (culture supernatant) or TNF-a standard

followed by 50

jl x I

of biotinylated anti-TNF-a antibody reagent were added to each well

of a 96-well plate, and incubated for two hours at room temperature (20-25°C). The plate
was washed three times with wash buffer after which 100 pi of streptavidin-horse radish
peroxidase (HRP) concentrate was added to all wells. Plate was incubated at room
temperature (20-25°C) for 30 minutes. After incubation, the plate was washed three times
again with wash buffer and incubated with 100 pi of tetramethylbenzidine (TMB)
substrate solution at room temperature (20-25°C), in the dark, for 30 minutes. The
reaction was stopped by the addition of 100 pi of stop solution to the wells and the O.D.
of the reaction mixture of each well was read at 450 nm using an ELISA reader MRX II
(Dynex Technologies Inc., Chantilly, VA). A standard curve was constructed by plotting
the

average

absorbance reading

obtained for each TNF-a

standard reaction

(concentrations of 0, 25.6, 64, 160, 400 and 1000 pg/ml) on the vertical axis against the
corresponding standard concentration on the horizontal axis. The standard curve was used
to determine the concentration of free TNF-a present in the test samples (culture
supernatants), from the absorbance readings at 450 nm obtained for each test sample. All
standards and test samples were run in duplicate. The detection sensitivity of the test is
<5 pg TNF-a/ml.

IFN-y Assay
A solid-phase ELISA using monoclonal antibodies against human IFN-y
(Endogen Inc., Woburn, MA) was performed to detect IFN-y in cell culture supernatants.
The assay was set up and carried out in a manner similar to the TNF-a assay, described
above. A PBMC suspension was prepared according to Protocol B and cell cultures

contained 1.36 x 106 cells/well. The concentrations of the standards used to generate the
standard curve were 0, 25.6, 64, 160, 400 and 1000 pg/ml. A standard curve was
constructed from the average absorbance reading obtained for each IFN-y standard
reaction (plotted on the vertical axis) against its corresponding concentration (horizontal
axis). The concentration of IFN-y present in the test samples (culture supernatants) was
determined from the absorbance readings at 450 nm obtained for each test sample. All
IFN-y standards and test supernatant samples were run in duplicate. The sensitivity of the
test was <5 pg IFN-y/ml.

IL-4 Assay
Human PBMC fraction of leukocytes were cultured in 24-well flat bottom tissue
culture plates. Cell cultures were set up in duplicate. Each well contained 200 pi of cell
suspension (2.2 x 105 cells/well or 1.36 x 106 cells/well prepared by Protocol B), 100 pi
of growth medium and 50 pi of test or control stimulant. Five pg/ml of ConA was added
to cultures as positive control to induce IL-4 production The culture plates were
incubated at 37°C for 4, 8, 20, 24, 30 and 48 hours in a humidified chamber with 5%
CO2 . At each specified time point, cells were harvested by aspirating the contents of each
well into a sterile microcentrifuge tube and centrifuging at 6,000 x g for 1 minute.
Culture supernatants were collected and stored in sterile microcentrifuge tubes at -80°C
until assayed for IL-4.
A solid-phase ELISA using monoclonal antibodies against human IL-4 (Endogen
Inc., Woburn, MA) was performed to detect IL-4 in cell culture supernatants. The assay
was set up as described above for IFN-y and TNF-a. The concentrations of the standards

used to generate the standard curve were 0, 10.24, 25.6, 64, 160 and 400 pg/ml. A
standard curve for IL-4 was constructed as described above for TNF-a, which was used
to determine the concentration of IL-4 present in the test samples (culture supernatants),
from the absorbance readings at 450 nm obtained for each test sample. All standards and
test samples were run in duplicate, and the sensitivity of the test was <2 pg IL-4/ml.

Isolation of Leukocyte DNA
Human PBL and PBMC fractions of leukocytes prepared by Protocols A and B
respectively were cultured in 24-well flat bottom tissue culture plates. Cell cultures were
set up in duplicate. Each well contained 200 pi of cell suspension (1.5 x 106 cells/well),
100 pi of growth medium and 50 pi of test stimulant. Positive control cultures for
apoptosis consisted of replacing the test stimulant (ASC) with 5 pM/ml of staurosporine
or 5 pg/ml of camptothecin. The culture plates were incubated at 37°C for 4 hours,
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hours, 24 hours and 48 hours in a humidified chamber with 5% CO2 . At each specified
time point, cells were harvested by resuspending and aspirating the contents of each well
into a sterile microcentrifuge tube. The DNA from test and control culture cells was
isolated using the protocol described in the apoptotic DNA ladder kit (Roche Diagnostics
Corporation, Indianapolis, IN). Cells undergoing apoptosis cleave their DNA into
fragments of 180-200 bp and multiples of this unit length, a characteristic that can be
visualized electrophorectically and used to identify apoptotic cells in a population. This
type of cleavage appears as a ladder of DNA fragment bands on agarose electrophoresis
gel. The DNA from the cultured PBMC treated with ASC was isolated following the kit
manufacturer’s instructions. DNA was examined for the appearance of a typical ladder of

fragment bands on agarose gel electrophoresis. Briefly, PBMC cultures were set up as
described above. Cultured cells were harvested and 200 pi of cell suspension was mixed
with

2 0 0

pi of the binding buffer and incubated for

10

minutes at room temperature (2 0 -

25°C). After incubation, 100 pi of isopropanol was added to the mixture, which was
vortexed for 30 seconds. A filter and a collection tube were combined to filter the ASC,
staurosporine and camptothecin stimulated test samples, along with the positive control
(apoptotic U937 cells) provided in the kit. The combined filter and collection tube set
was centrifuged for one minute at 6,000 x g. The filter tube contains glass fiber fleece to
which nucleic acids bind specifically to the surface of glass fibers in the presence of
chaotropic salts. The DNA immobilized on the filter was washed by passing 500 pi of
washing buffer twice through the fleece. Bound DNA was eluted with 200 pi of elution
buffer and recovered by centrifugation at

6 ,0 0 0

x g for one minute into a sterile

microcentrifuge tube. DNA concentration was calculated by diluting the sample 1:100 in
water and reading the absorbance at 260 nm. The concentration in pg/ml was calculated
by multiplying the absorbance at 260 nm by 50. The purity was estimated by dividing the
absorbance of the diluted sample at 260 nm by its absorbance at 280 nm. This ratio is of
1.8 or higher for pure samples of DNA and a ratio lower than 1.8 reflects sample
contamination with protein or phenol. DNA samples were stored at -20°C until
electrophoretic analysis in agarose gel electrophoresis was carried out.

Electrophoretic Analysis of DNA
A 1% agarose gel was prepared by mixing 0.5g of agarose (Sigma Chemical
Company, St. Louis, MO) with 50 ml of 40 mM Tris-Acetate containing 1 mM EDTA,

pH 8.3 (TAE Buffer Solution, Life Technologies, Rockville, MD). The agar mixture was
heated until the agarose was completely dissolved. The mixture was cooled to 60°C and
0.5 pg /ml of ethidium bromide was added. The melted agarose medium was poured into
a mounted electrophoresis chamber with the comb in place. The agarose gel was allowed
to solidify. TAE electrophoresis buffer was added to the chamber to a level, which
covered the agarose gel, the comb then was removed. Test samples and the positive
control (3 pg of purified DNA isolated from samples and control cells using the apoptotic
DNA ladder kit) diluted 1 to
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in loading buffer (0.02% bromophenol blue, 40% glycerol

in TBE [89 mM Tris, 89 mM boric acid, 2.5 mM EDTA, pH 8.0]) and loaded in to
separate wells. A molecular size marker (k DNA/Hind-III fragments, Life Technologies,
Rockville, MD) was run as a reference control for size of electrophoretic fragments.
Electrophoresis was carried out at 75 Volts for one hour at room temperature. The DNA
bands were visualized by placing the gel onto an UV light source and results recorded by
photographing the gel.

Statistical Analysis
Analysis of significance was performed using the Student’s paired t-test whenever
possible. Confidence limit of 95% was set to evaluate the data throughout this study.

R esults
Shark Cartilage Extract
An acid extract of shark cartilage (ASC) was prepared as described in Material
and Methods. Protein concentration of the preparation was determined by the BCAprotein assay after the extract was dialyzed against 400 ml of 0.02M Tris, pH 7.4. A
standard curve was generated using BSA standards (Figure 3), and the best points to
produce a straight line were calculated by linear regression. The absorbance reading at
562 nm for the ASC preparation was plotted on the standard curve and the protein
concentration determined. A protein concentration of 377 pg/ml was obtained (total
protein of 13.2 mg in 35 ml) for the preparation. This value is comparable to that (360
pg/ml) obtained by Simjee (Simjee, 1997) in an earlier study.

Endotoxin Assay
Each acid extract preparation of shark cartilage was tested for the presence of
endotoxin before it was used to stimulate human leukocytes in vitro. The detection
sensitivity for endotoxin of the E-Toxate test (Sigma Chemical Company, St. Louis, MO)
range from 0.05 to 0.1 EU/ml. Shark cartilage extract upon reaction with Limulus lysate
remained as a clear liquid or soft gel on completion of the test indicating that the extract
was free of any detectable endotoxin (Table 1). To eliminate the possibility of a negative
reaction being due to the presence of an E-Toxate inhibitor in the ASC extract, 0.01 ml of
the 4 EU/ml endotoxin standard was added to a duplicate sample of extract and tested for
the formation of a hard gel. The extract gave a positive reaction in this test.

0 -f-----------1----------- 1-----------1----------- 1----------- 1----------- 1
0

200
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1200

Concentration of BSA pg/ml
r = 0.999
Figure 3: Protein standard curve. A standard curve was constructed with varying
concentrations o f bovine serum albumin (BSA) as protein standards. Linear regression
was used to calculate the best points to produce a straight line on the standard curve. The
BCA-protein assay was used to determine the protein concentration of shark cartilage
extracts. The protein concentration was determined by plotting the absorbance readings at
562 nm for each sample on the standard curve. The protein concentration of the shark
cartilage extract was 377 pg/ml.

SAMPLE OR CONTROL

REACTION*

ASC
Test for E-Toxate inhibitor in ASC (sample
+ standard 4 EU/ml)
Negative Control (endotoxin-free water)
Standard 0.5 EU/ml
Standard 0.25 EU/ml
Standard 0.125 EU/ml
Standard 0.06 EU/ml
Standard 0.03 EU/ml
Standard 0.015 EU/ml

Soft gel

ENDOTOXIN (E) TEST
INTERPRETATION*
E absent

Hard gel

Absence of inhibitor

Liquid
Hard gel
Hard gel
Hard gel
Hard gel
Soft gel
Liquid

E absent
E present
E present
E present
E present
E absent
E absent

* Sensitivity o f the test: 0.05 - 0.1 EU/ml

Table 1: Endotoxin assay. Acid extract of shark cartilage was assayied for the presence
of endotoxin by employing E-Toxate kit. Reaction of each test sample and endotoxin
standards, when mixed with Limulus amebocyte lysate was recorded. A hard gel
formation represented a positive test for levels of endotoxin of > 0.05 EU/ml. All other
degree of gelation, ranging from fluid to soft gels, indicated absence of endotoxin oe
level < 0.05 EU/ml.

Comparison of Cell Separation Methods
Three different methods of cell separation were performed as described in
Material and Methods. Methods were compared with respect to the composition of the
cell population obtained, the yield and the viability of the human leukocytes. Leukocytes
from whole blood were separated by (a) Dextran sedimentation, or (b) Dextran
sedimentation followed by density gradient centrifugation using Histopaque, or (c)
density gradient centrifugation alone. Results are recorded in Table 2a and b and Figure
4a, b and c. For each cell suspension isolated, a manual total cell count was performed
and cell viability determined. To determine leukocyte yield, a total and differential count
was determined for whole blood. Differential count for fractionated leukocyte
populations was determined from cytospin monolayers of cells. When Dextran
sedimentation by itself was used to harvest leukocytes, the cell suspension was

heterogeneous and composed mostly of neutrophils with a high percentage of viable cells
recovered (Figure 4A). When the suspension was further fractionated on a Histopaque
gradient, a mononuclear cell fraction consisting primarily of lymphocytes with some
monocytes was obtained, however, a lower percentage of viable cells were recovered
(Figure 4b). Neutrophils were present in low numbers in this fraction. A mononuclear
cell fraction separated on a Histopaque gradient directly from blood yielded a cell
population of relatively high viability with significant yield from blood (Figure 4c). A
higher percentage of monocytes was recovered with a similar small number of
neutrophils remains in the fraction. The highest yield of total leukocytes was obtained
with Dextran, mononuclear cells were separated equally well by either Histopaque alone
or in combination with Dextran sedimentation. Protocols A and B were selected as
method of choice to isolate leukocyte fractions enriched for neutrophils (PBL) and
mononuclear cells (PBMC) respectively.

Viability and Proliferation of Leukocyte in culture
The viability and proliferation of cultured leukocytes grown in the absence of
stimulants was measured at 0, 4, 24, 30 and 48 hours of incubation. Cultures were set up
using a PBL fraction isolated by Protocol A, and PBMC fraction isolated by Protocol B.
Cell viability was determined by the trypan blue exclusion test, while cell proliferation
was measured by determining total cell counts manually. Results are recorded in Table 3.
Cell viability of PBL cultures decreased only slightly over 48 hours (98.5% to 94.4%),
with the PBMC culture viability being marginally less (96 to 94.5%) over the same time
period.

T otal W BC
count in
w hole blood
(cells/m l)cp

Total W BC
C ount in
separated cell
fraction*

D extran (PB L)
Protocol A

5 x 106

19.6 x 106
(PBL)

97.5

78

ND

H istopaque (PB M C )
Protocol B

5 x 106

3.7 x 106
(PBMC)

94

30

82

D extran+H istopaque
(PB M C ). Protocol C

5 x 106

2.7 x 106
(PBMC)

93

27

83

Total cell
viability

Total
W BC
yield

(%)

M ononuclear
cell yield
(%)

(%)

* Cells resuspended in 2 ml o f medium
cp W hole blood W BC count: 5 x 106 cells/ml containing 62% PMNs, 34% lymphocytes, 4% monocytes
ND: not done

a: Comparison of cell viability and leukocyte yield

Cytospin Film00
Mononuclear

Granulocytes
Neutrophils
(% )

Eosinophils

Lym phocytes

Monocytes

(%)

(% )

(%)

D extran (PBL)

73

3

17

7

H istop aqu e (PB M C )

4

0

71

25

D extran+H istopaque
(PB M C )

5

0

89

6

00200 cells counted
cp Whole blood W BC count: 5 x 106 cells/ml containing 62% PMNs, 34% lymphocytes, 4% monocytes

b: Comparison of cell types in fractionated leukocyte populations.

Table 2: Analysis of leukocyte fractions. Leukocyte suspensions isolated from whole
blood by dextran sedimentation (Protocol A), density gradient centrifugation on
Histopaque (Protocol B) and a combination of both (Protocol C), were compared for cell
viability and yield recovered (a), and composition and ratio of leukocyte types in the
fractions (b).
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The pattern of proliferation of the two leukocyte cultures, determined by cell counts,
however, differed significantly. PBL cell counts dropped significantly in the initial 24
hours and then total cell counts increased (Figure 5). The PBMC showed cell counts
dropped (50%) within 4 hours of culture, and then increased gradually over 48 hours
(Figure 6 ).

Morphology of Cultured Leukocytes
The in vitro cell cultures of PBL and PBMC fractions of whole blood that were
set up to assess proliferation were also examined for morphological changes of cell type
at 4, 20, 24, 30 and 48 hours. Cell cultures were used to prepare cytospin monolayers for
each sample, as described in the Material and Methods. Cytospin films were examined
for morphology of the leukocytes. Leukocytes of both fractions of PBL and PBMC
(Figure 7 a and b) in culture maintained normal morphology during the time periods
tested. However, by 48 hours it was noted that in the PBL cultures some cells, mainly
neutrophils, had a necrotic appearance while the majority of the PBL cells presented
normal morphology as illustrated in Figure 7a.

Effect of Shark Cartilage on in vitro Leukocyte Proliferation
The effect of shark cartilage on the in vitro proliferation of PBMC fraction of
leukocytes was measured using the MTT assay as described in the Material and Methods.
PBMC cell cultures grown in the presence of ASC showed the same proliferation rate as
these grown in the absence of ASC (Table 4), indicating that shark cartilage did not
inhibit normal cell proliferation under our experimental conditions.

Compared to cultures stimulated with ASC and in the absence of stimulant (control),
PBMC cultures stimulated with the mitogen LPS or ConA showed a rate and level of cell
proliferation over time, which statistically was not significantly different from that of
control cultures and ASC stimulated cultures. The lack of difference in the proliferative
response between the cultures was unexpected as ConA and LPS are mitogens known to
induce significant proliferative response and under our experimental conditions did not
do so. Thus, from results we can only say that ASC has no inhibitory effect (as cells grew
similar to control) but an ability for up regulation can not be ruled out.

ASC

Mean O.D.57o-63o nm

4 hours

24 hours

48 hours

4 hours

24 hours

48 hours

0.166

0.236

0.314

0.0.161

0.0.234

0.0.316

Pooled t value*
p value
Standard Error

Mean O.D.57o-63o nm
Pooled t value*
p value
Standard Error

Unstimulated Control

0.05

-

p > 0.05

-

0.04

-

LPS

ConA

4 hours

24 hours

48 hours

4 hours

24 hours

48 hours

0.145

0.185

0.209

0.148

0.212

0.233

1.15

1.08

p > 0.05

p > 0.05

0.02

0.03

* t value calculated using pooled-t test comparing ASC, LPS and ConA to unstimulated control

Table 4: Cell proliferation measured by MTT assay. Relative increase of in vitro
proliferation of human leukocytes (PBMC) cultured in triplicate for 48 hours in the
presence of ASC, LPS and ConA, or in the absence of any stimulant. Cultures were
seeded with 1.8 x 105 cells/well. Proliferation was determined by the MTT assay, which
measures the amount of reduced formazan by reading the absorbance of each sample
(triplicate readings of O.D.) at 570 nm with a reference filter of 630 nm.

TNF-a Secretion by Shark Cartilage-Stimulated Leukocytes
Levels of free TNF-a in culture supernatants were measured by ELISA, as
described in Material and Methods. Standard curves were generated using the TNF-a
standards, and the best points to give a straight line were calculated by linear regression
(Figure 8 ). When PBL fraction (2.4 x 105 cells/well) was cultured and stimulated with
ASC extract significant levels (p<0.05) of TNF-a was secreted in the culture supernatants
at 4 and
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hours of stimulation (Table 5), when compared to unstimulated culture

controls. At 20 hours, however, no free TNF-a could be detected in ASC culture
supernatants, whereas corresponding cultures stimulated with LPS showed high levels of
TNF-a at 20 hours with levels falling by 48 hours (Figure 9). The pattern of TNF-a
secretion by cultured PBMC (2.2 x 105 cells/well) stimulated with ASC extract was
different. The levels of TNF-a increased gradually over time reaching a peak at 20 hours.
Significant levels (p<0.05) of TNF-a was secreted and detected in culture supernatants
up to 48 hours, similar to TNF-a secretion by LPS-stimulated cultures (Table 6 ). No free
TNF-a was detected in supernatants of unstimulated cultures (Figure 10). The difference
in TNF-a secretion by the two types of cell culture (PBL and PBMC) can be explained
by the composition and cell type (relative numbers of mononuclear cells) present. It
should be noted that while TNF-a is a cytokine produced by a variety of cell types, the
primary source of this cytokine is monocytes/macrophages.

s

Concentration of TNF-a pg/ml
r = 0.974
Figure 8 : TNF-a standard curve. A standard curve was constructed using varying
concentrations of TNF-a standards. Linear regression was used to calculate the best
points to produce a straight line on the standard curve. This was used to determine the
concentration o f free TNF-a present in supernatants of PBL and PBMC cultures. TNF-a
concentration was determined by plotting the average absorbance reading at 450 nm
obtained for each sample on the standard curve and reading the corresponding
concentration o f TNF-a.

Mean O . D . 4 5 0 n m
TN F-a (pg/ml)
Paired t value
p value
Standard error
Cl*

Mean O.D. 4 5 0 nm
TN F-a (pg/ml)
Paired t value
p value
Standard error
Cl*

Mean O . D . 4 5 0 n m
TN F-a (pg/ml)

4 hours
0.377
18.07
30.6
<0.05

8

0 .6

14-22
4 hours
0.728
123
245
<0.05
0.5
119-126
4 hours
0.072
0

hours
0.393
22.5
45
<0.05
0.5
19-26

ASC00
2 0 hours
0.239

24 hours
0.197

48 hours
0.080

0

0

0

-

-

-

-

-

-

-

LPS00
2 0 hours
24 hours
1 .201
1.242
1.345
263
305
275
175
9.5
11
<0.05
<0.05
<0.05
1.5
32
25
253 - 272
103 - 507
117-433
Unstimulated Control
8 hours
2 0 hours
24 hours
0.085
0.080
0.079
8

hours

0

0

0

-

48 hours
0.438
63
125
<0.05
0.5
134 -206
48 hours
0.072
0

* Confidence Interval
00 Parameters were calculated from duplicate samples

Table 5: Production of TNF-a by PBL cultures. Levels of free TNF-a present in PBL
culture supernatants. Cell cultures initially contained 2.4 x 105 cells/well.

4 hours
0.973
195
32.5
<0.05

Mean O.D . 4 5 0 nm
TNF-a (pg/ml)
Paired t value
p value
Standard error
cr

157 -233

Mean O.D . 4 5 0 nm
TNF-a (pg/ml)
Paired t value
p value
Standard error
Cl*

4 hours
0.902
174
58
<0.05
3
155-193

Mean O.D . 4 5 0 nm
TNF-a (pg/ml)

4 hours
0.068
0
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ASC00
8 hours
2 0 hours
24 hours
1.001
1.568
1.324
204
372
300
81.4
5.8
46
<0.05
<0.05
<0.05
2.5
64.5
6.5
188-219
258 -341
-36 - 779
LPS00
8 hours
2 0 hours
24 hours
1.949
1.950
1.921
485
485
476
57
3174
7.8
<0.05
<0.05
<0.05
8.5
62
0 .2
431 - 538
94 - 876
475 - 477
Unstimulated Control
8 hours
2 0 hours
24 hours
0.078
0.09
0.078
0
0
0

48 hours
0.480
49
97
<0.05
0.5
4 5 -5 2
48 hours
0.908
176
117
<0.05
1.5
166-185
48 hours
0.073
0

* Confidence Interval
“ Parameters were calculated from duplicate samples

Table 6 : Production of TNF-a by PBMC cultures. Levels of free TNF-a present in
PBMC culture supernatants. Cell cultures initially contained 2.2 x 105 cells/well.

IFN-y Secretion by Shark Cartilage-Stimulated Leukocytes
Culture supernatants from PBMC (1.36 x 106 cells/well) were tested for the
presence of IFN-y. The solid-phase ELISA used for this purpose is described in Material
and Methods, and the standard curve generated from IFN-y standards is shown in Figure
11. IFN-y was not detected in ASC-stimulated or unstimulated control culture
supernatants at any time period of stimulation. Supernatants from cell cultures stimulated
with LPS (positive controls) contained significant levels (p<0.05) of IFN-y at 20, 24, 30
and 48 hours (Figure 12). It should be noted, however, that IFN-y was not detected at 4
hours in supernatants of the LPS-stimulated cultures. Furthermore, cultures for IFN-y
production were seeded with more cells/well (1.36 x 106) than cultures for TNF-a
production (2 . 2 x

10

5).

IL-4 Secretion by Shark Cartilage-Stimulated Leukocytes
The level of IL-4 in supernatants of PBMC cultures was determined by ELISA.
Cultures using two different cell densities (2.2 x 105 cells/well and 1.36 x 106 cells/well)
were set up. The standard curve used to determine the level of IL-4 in PBMC (2.2 x 105
cells/well) supernatants is shown in Figure 13. The level of IL-4 detected in culture
supernatants of PBMC stimulated with ASC extract was not statistically significant at any
of the time periods tested (Figure 14) from levels obtained for unstimulated control
culture. There was also no significant difference when compared to IL-4 levels produced
by ConA-stimulated cultures at 20, 24 and 48 hours. Furthermore, in cell cultures of
PBMC seeded with 2.2 x 105 cells/well, there was no detectable IL-4 in the supernatants
stimulated with PMA at any time period.

Concentration of IFN-y pg/ml
r = 0.999
Figure 11: IFN-y standard curve. A standard curve was constructed using varying
concentrations of IFN-y standards. Linear regression was used to calculate the best points
to produce a straight line on the standard curve. This was used to determine the
concentration of free IFN-y present in supernatants of PBMC cultures. IFN-y
concentration was determined by plotting the average absorbance reading at 450 nm
obtained for each sample on the standard curve and reading the corresponding
concentration o f IFN-y.

Concentration of IL-4 pg/ml
r = 0.999
Figure 13: IL-4 standard curve. A standard curve was constructed using varying
concentrations o f IL-4 standards. Linear regression was used to calculate the best points
to produce a straight line on the standard curve. This was used to determine the
concentration o f free IL-4 present in supernatants of PBMC cultures (2.2 x 105
cells/well). IL-4 concentration was determined by plotting the average absorbance
reading at 450 nm obtained for each sample on the standard curve and reading the
corresponding concentration o f IL-4.

Concentration of IL-4 pg/ml
r = 0.999
Figure 15: IL-4 standard curve. A standard curve was constructed using varying
concentrations of IL-4 standards. Linear regression was used to calculate the best points
to produce a straight line on the standard curve. This was used to determine the
concentration o f free IL-4 present in supernatants o f PBMC cultures (1.36 x 106
cells/well). IL-4 concentration was determined by plotting the average absorbance
reading at 450 nm obtained for each sample on the standard curve and reading the
corresponding concentration of IL-4.

In an attempt to increase detection of significant levels of IL-4 in the supernatants
cell cultures were set up seeded with an increased number of PBMC. Cultures seeded
with 1.36 x 106 cells/well were stimulated with ASC extract and supernatants for assayed
IL-4. The standard curve constructed for this assay is shown in Figure 15. Again, there
was no detectable free IL-4 in the supernatants stimulated with ASC extract (Figure 16),
however, significant levels (p<0.05) of IL-4 were detected in supernatants from cultures
stimulated with Con A, which peaked at 20 hours and gradually declined thereafter.
Unstimulated cell cultures produced no detectable IL-4 in culture supernatants.

Apoptosis in ASC Stimulated Leukocyte Cultures
Morphological Assessment
Cytospin monolayers of PBL cultures were prepared as described in the Material
and Methods, and examined for the typical morphological changes that are characteristic
of leukocytes undergoing apoptosis. PBL (1.7 x 106 cells/well) were cultured for four
hours in the presence of ASC extract, or different concentrations (0.5, 1.0, 5.0 and 10
pM/ml) of staurosporine, which was used as an inducer of apoptosis. Results are recorded
in Table 7. Morphological changes typical of apoptosis, such as reduction in cell volume,
nuclei shrinkage and nuclear fragmentation were observed in some cells present in the
cytospin preparations. A statistically significant difference was noted in the number of
apoptotic cells present in ASC-stimulated cultures and the number observed in the
unstimulated control culture. Furthermore, no statistically significant difference was
noted in the number of apoptotic cells present in cartilage-stimulated leukocyte cultures
and those stimulated with 0.5 pM/ml of staurosporine. At four concentrations tested,
staurosporine induced significant apoptosis in PBL cultures when compared to the

unstimulated culture control. The percentage of apoptotic cells present in staurosporinestimulated cultures at 4 hours was similar (25-29%) for staurosporine concentrations
ranging from 1.0 pM/ml up to 10 pM/ml. The apoptotic changes noted in PBL cultures at
4 hours are illustrated in Figure 17.

SAMPLES AND
CONTROLS
Unstimulated Control00
Staurosporine (0.5 pM/ml)00
Staurosporine (1 pM/ml)
Staurosporine (5 pM/ml)
Staurosporine (10 pM/ml)
Stimulated with ASC00

APOPTOTIC
CELLS (%)
2.4
7.4
27
25
29
6.2

t value

Standard Error

-

0.52
0.94
ND
ND
ND
0.81

3.57
ND
ND
ND
4.34

ND: not done
Total o f 100 PBL were counted to calculate the percentage o f viable and apoptotic cells.
00 Difference between Staurosporine 0.5 p.M/ml and ASC-stimulated cultures is not statistically significant (p >0.05);
however, between them and the unstimulated control culture is significant (p<0.05).

Table 7 Apoptotic cells in PBL cultures. The relative number of apoptotic cells present in
leukocyte populations (2.4 x 105 PBL/well) when cultured in vitro for 4 hours at 37°C in
the presence of shark cartilage extract (ASC) or different concentrations of staurosporine
(0.5-10 pM/ml). Unstimulated control cultures were grown in medium alone.

PBMC (1.63 x 106 cells/well) were cultured for 24 hours in medium alone, in the
presence of shark cartilage, staurosporine (5 pM/ml) or camptothecin (5 pg/ml). The
latter were used to induce apoptosis. Cytospin monolayers were prepared and
microscopically examined for cells showing typical apoptotic changes in the form of
cytoplasmic constriction, blebbing, chromatin condensation and nuclear fragmentation.
Results are recorded in Table

8

and illustrated in Figure 18. The few apoptotic cells

observed in the cytospin preparation of unstimulate cultures is to be expected.

SAMPLES AND CONTROLS
Negative Control
Staurosporine (5 pM/ml)
Camptothecin (5 pg/ml)
ASC

APOPTOTIC CELLS (%)
2
24
11
6

Total o f 100 PBMC were counted to calculate the percentage o f viable and apoptotic cells.

Table 8 Apoptotic cells in PBMC cultures. The relative number of apoptotic cells present
in leukocyte populations (1.63 x 106 PBMC/well) when cultured in vitro for 24 hours at
37°C in the presence of shark cartilage extract (ASC) or staurosporine (5 pM/ml) and
camptothecin (5 pg/ml). Unstimulated control cultures were grown in medium alone.

Assessment by DNA Fragmentation Pattern
DNA from PBMC cultures stimulated with ASC extract for 4, 8 , 24 and 48 hours
was isolated using the Apoptotic DNA Ladder kit, as described in the Material and
Methods. Eletrophoretic analysis in agarose gel was performed to observe DNA
fragmentation, which when present has the appearance of a typical apoptotic ladder
formation exhibited by DNA extracted from U937 cells provided in the kit as a DNA
fragmented control (Figure 19, lane 2). Staurosporine (5pM/ml) and camptothecin
(5 pg/ml) stimulated cell cultures were set up as positive culture controls for the cell
population under study (PBMC). DNA ladder formation was not observed in DNA
obtained from unstimulated, ASC-stimulated cultures or cultures treated with either
staurosporine or camptothecin and incubated for
6

8

hours (Figure 19 a, lanes 1, 3, 4, 5 and

respectively). The typical DNA ladder formation could only be observed with DNA

extracted from the apoptotic cells provided as a control (Figure 19a, lane 2).
A hind III digest of X DNA was run as molecular size marker (lane 7). At 24
hours, evidence for typical DNA ladder formation could not be seen for ASC,
staurosporine and camptothecin stimulated cultures (Figure 19b, lanes 1, 3 and 4).

However, these appeared to be a reduction in the brightness/intensity of the starting
material DNA band (when compared to DNA from earlier cultures) indicating some loss
of high molecular size DNA. At 48 hours, a significant decrease in the staining intensity
of sample DNA from ASC and staurosporine stimulated cultures (Figure 19b, lane

6

and

7 respectively) was noted, along with presence of faint bands of lower molecular size
DNA (i.e. fragments), particularly for the staurosporine stimulated culture. A decrease in
the amount of sample DNA from unstimulated culture was also noted, however, it was
significantly less (Figure 19b, lane 5). This was to be expected given (a) unstimulated
cells normally undergo apoptosis, and (b) morphological examination of cytospin
monolayers of unstimulated cultures had shown presence of a few apoptotic cells.

Discussion
Shark cartilage, available commercially as a food supplement, is classified by the
NCCAM as a biological-based therapeutic substance under the practice of Alternative
Medicine. Shark cartilage is not only used as a therapeutic agent for the treatment of
rheumatoid arthritis, psoriasis, scleroderma, AIDS, and certain cancers, but also for
prophylactic purposes by healthy individuals. The therapeutic and prophylactic use of
shark cartilage is increasing among the general population, even though its effectiveness
has not been definitively proven. Shark cartilage, however, has been shown to inhibit
angiogenesis (Berbari et al., 1999), modulate the immune system (Fontenele et al., 1997
and serve as a scavenger of oxygen reactive species (Felzenszwalb et al., 1998). The
focus of most shark cartilage studies is on its use as an angiogenesis inhibitor. Little is
known about its short and long term effects on the immune system of healthy individuals,
particularly on leukocyte function.
Previous studies showed that different preparations of shark cartilage extracts
(acid, salt-soluble and phosphate-buffered saline extracts), stimulated human leukocytes
in vitro to release significant levels of TNF-a after 24 and 48 hours of incubation, with
the highest cytokine response obtained with the acid extract (Simjee, 1997; Simjee and
Smith, 1997). This earlier study had also shown that the “active” component in the
extracts was susceptible to digestion with proteolytic enzymes, suggesting it to be
proteinaceous in nature. To study further the in vitro effect of shark cartilage on human
leukocytes, we investigated the production and release of IL-4 and INF-y by leukocytes
following stimulation with acid extract of shark cartilage. Furthermore, the present study

also undertook to examine treated cells for evidence of apoptosis and a proliferative
response.
The ASC reagent prepared for this study had a protein concentration similar to
that of the ASC preparation used in the previous study. The shark cartilage extract was
tested for endotoxin before it was used to stimulate leukocytes in vitro. This was done to
rule out the possibility of the cellular response being due to contaminating endotoxin
present in the ASC preparation. The ASC reagent was determined to be relatively free of
endotoxin using the E-Toxate kit, which detects endotoxinn levels as low as 0.05 EU/ml,
a level considered to be lower than the threshold required to stimulate cells. We are
reasonably certain (considering the results obtained from our control culture) that the
effects of stimulation noted are due directly to ASC and not from the presence of
endotoxin contaminating the preparation.
Cell suspensions for in vitro culture were prepared by two different methods of
cell separation: Dextran sedimentation, which produced a heterogeneous population of
leukocytes rich in polymorphonuclear neutrophils (PMNs), and density gradient
centrifugation (using Histopaque), which yielded a leukocyte fraction rich in
mononuclear cells. We decided to use two different cell fractions in order to maximize
our experimental conditions to include optimal cell types required to produce detectable
levels of cytokines in culture supernatants. When stimulated with LPS, TNF-a is
primarily produced by mononuclear cells. However, it is also produced by many other
cell types such as neutrophils and NK cells which makes it reasonable to use both PBL or
PBMC fractions to determine if anyone population (enriched for a certain cell type)
showed enhanced response to LPS or other stimulant. IFN-y and IL-4 are cytokines

produced by more restricted cell populations. IL-4 is almost exclusively produced by T
cells and IFN-y by T cells and NK cells, making culture of PBMC fraction more suitable
for the study of these cytokines.
The in vitro cell proliferation and viability were evaluated by performing manual
cell counts in parallel with cell culture for cytokine production in order to confirm that
the cells were able to grow in our system. Initially viability tests on the cells in culture
showed them to be dying after a few hours of incubation, which was believed to be due to
insufficient CO 2 present in the growth chamber. Once cultures were maintained in a CO2
incubator with constant level of gas and humidity, the growth of leukocytes for longer
periods was achieved as seen by the increase in cell numbers determined by manual cell
count. The approximate number of cells in a cell suspension can be estimated by a
manual cell count. While this method is not as accurate method as flow cytometry, for the
purpose of our study this method was valuable to determine cell proliferation in the
cultures and to confirm that the leukocytes in culture were viable and able to proliferate
under our experimental conditions. In cultured PBL fraction, the number of PMNs in the
harvested cells dropped within the first 24 hours and then there was an apparent increase
in number seen at 48 hours. On the other hand, the number of lymphocytes continued to
increase gradually over 48 hours, reaching numbers similar to PMNs, which originally
was the predominant cell type in this fraction. In the corresponding cytospin monolayers
of this fraction, this change of predominance in cell type was confirmed. There are two
possible explanations for the observations noted. First, PMNs being terminal cells might
well be expected to die, and are being substituted by proliferating mononuclear cells, thus
maintaining total cell numbers. Secondly, PMNs could be sticking firmly to the bottom

surface of the cell culture wells and not being “harvested”. The latter is probably the
more reasonable explanation due to the fact that the cell viability was high, implying that
cells were not dying in the culture. The apparent increase, proportionately of PMNs in
later culture might be that older cells are easily dislodged.
Along with cell viability and proliferation, cell morphology was evaluated by
cytochemical analysis using cytospin monolayers obtained from cell suspensions
harvested from untreated cultures, to reaffirm that our experimental conditions were
optimal for cell maintenance and growth. As shown in Results, PBL and PBMC cell
cultures had normal morphology indicating that the cells were viable and metabolically
capable. The MTT assay is a more accurate method to evaluate cell proliferation than
manual cell counts, as it is a colorimetric assay that measures the amount of formazan
reduced by viable cells. The amount, therefore, of formazan reduced is directly
proportional to the number of viable/metabolizing cells in culture. This method was
selected to evaluate the effect of shark cartilage on leukocyte proliferation. Under our
experimental conditions, in vitro leukocyte proliferation, measured by the MTT assay,
was not inhibited by shark cartilage, when proliferation was compared to that obtained
with unstimulated cultures. Unexpectly however, cell proliferation was not enhanced in
the presence of mitogens LPS and ConA, which are typically used to induce increased
cell proliferation.
Culture of PBL was set up to confirm that under our experimental conditions
TNF-a could be induced by our preparations of ASC similar to the results obtained
previously in our laboratory. This was the case, however, the pattern of cytokine
production (biphasic) was not seen. Cultured PBMC were stimulated with ASC to

determine whether the type of cell influenced the cellular response (i.e. TNF-a secretion)
to ASC. Like previous studies, PBL when stimulated with ASC, produced TNF-a,
however, the biphasic response noted in earlier studies where TNF-a levels peaked at

8

and 24 hours with a drop at 12 hours was not noted. Under our experimental conditions,
the level of TNF-a peaked at 20 hours with no drop being noted before a peak. It should
be noted, however, that in this study culture supernatants were not assayed for TNF-a at
12

hours, and it is possible that during the

12

-hour period, levels did drop but could not

be noticed. PBMC cultures were stimulated with ASC (and LPS and ConA) to detect IL4 and IFN-y production, as IL-4 and INF-y are cytokines produced by T cells primarily.
PBMC fraction is a mononuclear cell enriched preparation and contains primarily
lymphocytes.
The pattern of cytokine production obtained in our study was different from the
one obtained previously. We detected TNF-a in culture supernatants up to

8

hours after

stimulation with ASC when PBL was used, as opposed to Simjee and Smith, who
detected this cytokine up to 30 hours after stimulation with acid shark cartilage extract.
The different pattern obtained in the two studies could be explained by (a) differences in
the composition of the ASC extract, considering that these are crude extracts and might
have differences in their components, stimulating cells to produce cytokines at different
levels, (b) different responding cells, considering individual differences in cytokine
production by different subjects who donated cells for the two studies and (c) difference
in the PBL fraction composition, which could be richer in mononuclear cells in the earlier
study compared to ours, which was mostly composed by PMNs. We also compared TNF-

a response by ASC-stimulated PBMC. With this cell population, we detected high levels
of TNF-a in the culture supernatants stimulated with ASC and LPS up to 48 hours of
incubation. This result can be readily explained by the difference in cell population
between PBL and PBMC. TNF-a is a cytokine produced primarily by mononuclear cells,
which are present in higher concentration in the PBMC preparation. The concentration in
pg/ml of TNF-a obtained in culture supernatants from both PBL and PBMC stimulated
with either ASC or LPS during this study was lower for all time periods than the
concentration obtained in the previous study of both stimulants. This could be explained
the fact that as we did not detect TNF-a after

8

hours in the PBL fraction like previously,

there was an extended lag period.
We decided to test for IL-4 production by ASC-stimulated PBMC because, unlike
TNF-a, IL-4 is a cytokine that is characteristic of the development of Th-2 type of
immune response, which in turn leads to the development of an anti-inflammatory
response with concomitant production of antibodies. Conversely, TNF-a is a Th-1 type
of cytokine that leads to the development of an inflammatory response after antigen
stimulation, with the presence of cytotoxicity and development of delayed-type
hipersensitivity. We were unable to detect free IL-4 in culture supernatants from cells
stimulated with ASC in our system. Although this cytokine was not detected, we cannot
rule out definitely the possibility that ASC induces the production of IL-4. It is possible
that the cells need to be stimulated for longer periods to produce IL-4 at detectable levels
in our culture system. Mosmann and Coffman (1989) examined the lymphokine profiles
of helper clones from

2

to

6

weeks after establishment in culture, in some experiments,

they could not detect a recognizable Th-1 or Th-2 response at the early times, however,
the cell clones sometimes changed into clear Th-1 or Th-2 phenotypes on continued
growth in culture. They proposed a model in which a single precursor cell gives rise to
either Th-1 or Th-2 cells depending upon the antigen-presenting cell. The precursor cells
synthesize a set of lymphokines that fit neither Th-1 or Th-2 patterns. In other words,
memory T cells synthesize cytokines that fit a Th-1 or Th-2 pattern and unprimed T cells
synthesize cytokines at similar levels that do not necessarily fit any specific pattern.
Because results of IL-4 production by ASC-stimulated cultures was inconclusive,
we decided to investigate a second Th-1 type of cytokine in an attempt to establish a
pattern of Th-1 response. We elected to assay for IFN-y in culture supernatants since this
cytokine inhibits the proliferation of Th-2 cells, indicating that its presence will result in
the preferential expansion of Th-1 cells during an immune response (De Maeyer and De
Maeyer-Guignard, 1998; Gehring et al., 1998). Contrary to expectations, IFN-y could not
be detected in ASC-stimulated culture supernatants after 48 hours of incubation. These
negative results can be interpreted in three different ways: (1) ASC does not stimulate
either IL-4 or IFN-y production by human PBMC, (2) there was not enough time
provided under our experimental conditions for the cells to release these cytokines in the
culture supernatants, and (3) background immunity of donors, which leads to the
production of Th-1 or Th-2 clones preferably, depending on the antigenic stimulation and
ongoing immune response at the time cells were collected. The investigation of the
development of human T cell differentiation using freshly isolated cells, especially in its
early phase, is not an easy task. It is not clear if polyclonal activation of naive T cells by
mitogens mimic physiological activation, which is triggered by HLA-TCR contact

between the antigen-presenting cell and the T cell, in this system (Gehring et al., 1998).
Cytokine profiles of helper clones in cultures are sometimes not recognizable Th-1 or Th2 at early times (Mosmann and Coffman, 1989), however they can change into clear Th-1
or Th-2 phenotypes on continued growth in culture. In addition, there are reports of
clones that secrete a mixture of the two patterns (Paliard et al., 1988; Maggi et al., 1988).
During this study, apoptosis in leukocytes stimulated with shark cartilage was
assessed morphologically and by DNA fragmentation pattern. We found characteristic
morphological changes indicative of apoptosis in leukocytes following incubation with
shark cartilage. A statistically significant difference was not noted in the number of
apoptotic cells present in cartilage-stimulated leukocyte preparations and those stimulated
with 0.5 p.M/ml of staurosporine, suggesting that shark cartilage induces apoptosis in
human leukocytes. ASC did not induce apoptosis at a level obtained with higher
concentrations of staurosporine. This result implies that the apoptosis inducer present in
the ASC preparation could be in low concentrations. When cytospin monolayers from
cultures containing apoptosis inducers or ASC was examined, they revealed apoptotic
morphological changes more frequently present in mononuclear cells than in PMNs.
PMns are terminal cells, therefore, they do not enter the cell cycle as mononuclear cells.
As a result, the latter can be detected undergoing apoptosis more frequently.On the other
hand, DNA fragmentation could not be demonstrated for either cartilage-stimulated cells
or staurosporine-stimulated cells. Although oligonucleosomal cleavage accompanies
apoptosis in most systems, it has been reported that apoptosis can occur in the absence of
intemucleosomal fragmentation (Oberhammer et al, 1993). The detection of the typical
pattern of DNA ladder on agarose gel requires a large number of cells undergoing

apoptosis to be visualized. Some protocols use 20 x 106 cells to be able to detect the
typical ladder on the agarose gel (Wolfe et al, 1996). In our system we used 1.5 x 106
cells, which probably was not enough to show the typical DNA ladder. The induction of
apoptosis on human leukocytes by ASC has an important relevance for cancer treatment.
Apoptosis has been studied as an alternative for cancer treatment and prevention by
controlling cell proliferation, which is a crucial process during tumor growth and
development (Martin and Green, 1994; Mori et al., 1999). The induction of apoptosis by
shark cartilage could justify its use in cancer treatment. Besides, TNF-a has been shown
to induce apoptosis in some cell types, including endothelial cells (Polunovsky et al.,
1994; Schwartz et al., 1999), which also could explain the use of shark cartilage for
cancer treatment knowing that shark cartilage induces the production of TNF-a.
During this study, we confirmed that a crude acid extract of shark cartilage
stimulates TNF-a production in vitro by human leukocytes, as shown previously in our
laboratory. We could not detect IL-4 or IFN-y in supernatants from cultures stimulated
with shark cartilage, therefore, being unable to establish a Th-1 or Th-2 patter of cytokine
response, detecting only one type of Th-1 cytokine. The production of IL-4 and IFN-y by
shark cartilage-stimulated human leukocytes in vitro needs to be further studied in order
to give a more definitive conclusion. We could also conclude that shark cartilage induced
apoptosis in human leukocytes in vitro, in a similar fashion to 0.5 pM/ml of
staurosporine.
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Appendix i
FOR CONSUMERS AND PRACTITIONERS
. CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE

M ajor D o m a in s of Com plem entary & A lte rn a tiv e M ed icin e

Complementary and alternative healthcare and medical practices (CAM) are those
healthcare and medical practices that are not currently an integral part of conventional
medicine-. The list of practices that are considered CAM changes continually as CAM
practices and therapies that are proven safe and effective become accepted as
"mainstream" healthcare practices. Today, CAM practices may be grouped within five
major domains-: ( 1 ) alternative medical systems, (2 ) mind-body interventions, (3 )
biologically-based treatments, (4) manipulative and body-based methods, and (5) energy
therapies. The individual systems and treatments comprising these categories are too
numerous to list in this document. Thus, only limited examples are provided within
each.
I. ALTERNATIVE MEDICAL SYSTEMS

Alternative medical systems involve complete systems of theory and practice that have
evolved independent of and often prior to the conventional biomedical approach. Many
are traditional systems of medicine that are practiced by individual cultures throughout
the world, including a number of venerable Asian approaches.
Traditional oriental medicine emphasizes the proper balance or disturbances of qi
(pronounced chi), or vital energy, in health and disease, respectively. Traditional oriental
medicine consists of a group of techniques and methods, including acupuncture, herbal
medicine, oriental massage, and qi gong (a form of energy therapy described more fully
below). Acupuncture involves stimulating specific anatomic points in the body for
therapeutic purposes, usually by puncturing the skin with a needle.
Ayurveda is India’s traditional system of medicine. Ayurvedic medicine (meaning
"science of life") is a comprehensive system of medicine that places equal emphasis on
body, mind, and spirit, and strives to restore the innate harmony of the individual. Some
of the primary Ayurvedic treatments include diet, exercise, meditation, herbs, massage,
exposure to sunlight, and controlled breathing.
Other traditional medical systems have been developed by Native American, Aboriginal,
African, Middle-Eastern, Tibetan, Central and South American cultures.
Homeopathy and naturopathy are also examples of complete alternative medical
systems. Homeopathy is an unconventional Western system that is based on the
principle that "like cures like," i.e., that the same substance that in large doses produces
the symptoms of an illness, in very minute doses cures it. Homeopathic physicians
believe that the more dilute the remedy, the greater its potency. Therefore, homeopaths
use small doses of specially prepared plant extracts and minerals to stimulate the body’s

Naturopathy views disease as a manifestation of alterations in the processes by which
the body naturally heals itself and emphasizes health restoration rather than disease
treatment. Naturopathic physicians employ an array of healing practices, including diet
and clinical nutrition; homeopathy; acupuncture; herbal medicine; hydrotherapy (the use
of water in a range of temperatures and methods of applications); spinal and soft-tissue
manipulation; physical therapies involving electric currents, ultrasound, and light
therapy; therapeutic counseling; and pharmacology.
II. MIND-BODY INTERVENTIONS

Mind-body interventions employ a variety of techniques designed to facilitate the mind’s
capacity to affect bodily function and symptoms. Only a subset of mind-body
interventions are considered CAM. Many that have a well-documented theoretical basis,
for example, patient education and cognitive-behavioral approaches are now considered
"mainstream." On the other hand, meditation, certain uses of hypnosis, dance, music,
and art therapy, and prayer and mental healing are categorized as complementary and
alternative.
III. BIOLOGICAL-BASED THERAPIES

This category of CAM includes natural and biologically-based practices, interventions,
and products, many of which overlap with conventional medicine’s use of dietary
supplements. Included are herbal, special dietary, orthomolecular, and individual
biological therapies.
Herbal therapies employ individual or mixtures of herbs for therapeutic value. An herb
is a plant or plant part that produces and contains chemical substances that act upon the
body. Special diet therapies, such as those proposed by Drs. Atkins, Ornish, Pritikin, and
Weil, are believed to prevent and or control illness as well as promote health.
Orthomolecular therapies aim to treat disease with varying concentrations of chemicals,
such as, magnesium, melatonin, and mega-doses of vitamins. Biological therapies
include, for example, the use of laetrile and shark cartilage to treat cancer and bee pollen
to treat autoimmune and inflammatory diseases.
IV. MANIPULATIVE AND BODY-BASED METHODS

This category includes methods that are based on manipulation and/or movement of the
body. For example, chiropractors focus on the relationship between structure (primarily
the spine) and function, and how that relationship affects the preservation and
restoration of health, using manipulative therapy as an integral treatment tool. Some
osteopaths, who place particular emphasis on the musculoskelatal system, believing that
all of the body’s systems work together and that disturbances in one system may have an
impact upon function elsewhere in the body, practice osteopathic manipulation. Massage
therapists manipulate the soft tissues of the body to normalize those tissues.

Energy therapies focus either on energy fields originating within the body (biofields) or
those from other sources (electromagnetic fields).
Biofield therapies are intended to affect the energy fields, whose existence is not yet
experimentally proven, that surround and penetrate the human body. Some forms of
energy therapy manipulate biofields by applying pressure and/or manipulating the body
by placing the hands in, or through, these fields. Examples include Qi gong, Reiki and
Therapeutic Touch. Qi gong is a component of traditional oriental medicine that
combines movement, meditation, and regulation of breathing to enhance the flow of
vital energy (qi) in the body, to improve blood circulation, and to enhance immune
function. Reiki, the Japanese word representing Universal Life Energy, is based on the
belief that by channeling spiritual energy through the practitioner the spirit is healed,
and it in turn heals the physical body. Therapeutic Touch is derived from the ancient
technique of "laying-on of hands" and is based on the premise that it is the healing force
of the therapist that affects the patient’s recovery and that healing is promoted when the
body’s energies are in balance. By passing their hands over the patient, these healers
identify energy imbalances.
Bioelectromagnetic-based therapies involve the unconventional use of electromagnetic
fields, such as pulsed fields, magnetic fields, or alternating current or direct current
fields, to, for example, treat asthma or cancer, or manage pain and migraine headaches.

1 The term conventional medicine refers to medicine as practiced by holders o f M.D. (medical doctor) or
D.O. (doctor o f osteopathy) degrees, some o f whom may also practice complementary and alternative
medicine. Other terms for conventional medicine are allopathy, Western, regular, and mainstream
medicine, and biomedicine.
[ Return to CAM Domains ]
2 These are the categories within which NCCAM has chosen to group the numerous CAM practices;
others employ different, broad groupings.
[ Return to CAM Domains ]
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So far, over 550 patients have been given the drug in clinical studies in Canada
and the United States, some of them for more than 3 years. These studies
indicate that/E-941 has a good safety and tolerability profile, both alone and in
combination with chemotherapy and radiotherapy treatments.
Oncology (7E -941/N eovastat)
After having completed a Phase I/II trial in lung and prostate cancer, and a
Phase I trial in breast cancer during 1999, as scheduled, /Eterna has received
approval from the Health Protection branch (HPB) in Canada, and the Food and
Drug Administration (FDA) in the United States to begin a Phase III trial of/E941/Neovastat in lung cancer patients.
This trial is sponsored by the U.S. National Cancer Institute (NCI) and will focus
on the use of /E-941/Neovastat together with chemotherapy and radiotherapy
to treat lung cancer. It will be a double-blind placebo-controlled study involving
approximately 800 patients with non-operable non-small-cell lung cancer. The
patients will be administered standard chemotherapy and radiotherapy and
randomized in two groups. One group will be administered Neovastat and the
other a placebo. The primary endpoint will be survival. The study will involve
over 60 hospitals and cancer centers in the U.S. and Canada. Recruitment will
be coordinated through the Community Cooperative Oncology Program (CCOP)
of the MD Anderson Cancer Center.
Applications to begin another Phase III trial of /E-941/Neovastat have also
been filed for the treatment of patients with progressive renal cell carcinoma.
Renal cell carcinoma is the most common type of kidney cancer in adults which
affects approximately 34,000 people a year in North America. At the moment,
there are few therapies available for RCC. These therapies have serious side
effects and only a small number of patients treated respond to the therapy.
This trial is expected to begin in North America and Europe shortly after
receiving approval from the HPB and the FDA and will take place in about 40
investigative sites involving approximately 270 patients.
Clinical data sum m ary. Over 450 patients have been exposed to the drug
and some with an exposure of more than three years. The optimum dose to
perform pivotal studies was determined without limitations due to toxicity.
Study d etails.

Breast, lung or prostate cancer. Phase I/II
This study was a multi-center, open-label, dose-ranging study for the
evaluation of the safety, tolerability and efficacy of Neovastat. The compound
was administered orally for 12 weeks in patients with solid tumors of the
breast, lung or prostate that were refractory to standard therapies, or for
whom there were no standard therapies available.
The objectives of the study were to assess the safety and tolerability of
Neovastat at four different doses in these patients, and to obtain preliminary
information on the efficacy of Neovastat in order to select the dose for Phase

Breast cancer cohort. The Phase I of the breast cancer cohort was closed in
June 1998. Because many other treatments currently approved or under
investigation are also accessible to that patient population, it was decided in
June 1998 not to proceed with Phase II of the breast cancer cohort.
Lung cancer cohort. A total of 43 patients were recruited from December 1996
to October 1997. An interim analysis was performed at the end of Phase I to
determine the dose to be administered during Phase II of the study. A positive
dose response was established during interim analysis, in favor of the highest
dose. The clinical index score was improved by more than 50% at the highest
dose compared to the lowest dose. The absence of significant toxicity and the
preliminary efficacy data prompted the choice of the highest dose (240
mL/day) as the optimal dose for the Phase II of the study.
A total of 37 additional patients were recruited from January 1998 to June
, 1998, with 21 patients completing 84 days of treatment at a dose of 240
mL/day.
Results from a retrospective analysis of the lung cancer cohort suggested that
the higher doses (240 mL per day) of Neovastat significantly increased the
median survival time by 47%, as compared to lower doses in patients with
refractory non-small-cell lung cancer (locally recurrent or metastatic). The data
also confirmed the appropriateness of the dose which will be used in a
randomized double-blind placebo-controlled Phase E l trial to be started shortly.

Prostate cancer cohort. A total of 34 patients were recruited from March 1997
to March 1998. Of those, a total of 22 patients completed 84 days of
treatment. An interim analysis was performed at the end of Phase I to
determine the dose to be administered in Phase II of the study. Similar to the
observations in the lung cancer cohort, oral administration of Neovastat
resulted in a favorable safety profile, and showed a positive trend in favor of a
dose-related therapeutic benefit.
A total of 38 additional patients were recruited from June 1998 to October
1998, with 20 patients completing 84 days of treatment at a dose of 240
ml/day. Results will be presented shortly.

Special access program
The special access program allows physicians to request drugs not approved in
Canada in order to treat patients suffering from serious or life threatening
illne-jus wheie standard therapies have failed or are unsuitable. The safety
and efficacy parameters in this study are similar to those listed above. . The dose of Neovastat used in this program was 60 mL/day as an open-ended
treatment. Over 100 physicians have presented such a request to the SAP for
patients with different types of solid tumors. The program started in August
1996 and ended in June 1997 after including 150 patients. Based on data from
the lung cancer patient cohort and the prostate cancer patient cohort described
in the above study, all cancer patients participating in this trial had their dose
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increased to 240 mL/day. As of June 1999 eight patients were still receiving
Neovastat. Some of the patients in the study received chemotherapy in
combination with Neovastat.

Refractory solid tumors Phase I
The clinical trial using Neovastat for the treatment of refractory solid tumors in
combination with currently available treatments is still ongoing but the
recruitment is completed. In this trial, Neovastat is administered daily at oral
doses of 240 ml/day. The objective of this clinical trial is to evaluate the long
term safety of Neovastat in combination or monotherapy in the treatment of
refractory solid tumors.
Dermatology
/Eterna's focus is moderate to severe plaque psoriasis. The convenience of oral
administration and low toxicity associated with /E-941/Neovastat are essential
for patients who will be taking this medication over long periods. A randomized,
dose-ranging Phase I/II monotherapy trial for /E-941/Neovastat has been
completed.
Clinical data summary. Results from a Phase I/II clinical trial outlined /E941/Neovastat/s safety and tolerability, and indicated preliminary signs of
efficacy. No serious adverse side effects were identified at any dosage level
during the first three months of the trial. A total of 30 patients were evaluated.
These results revealed that /E-941/Neovastat had a positive statistically
significant effect on the condition of patients suffering from psoriasis with
regards to the PASI score (Psoriasis Area and Severity Index). The PASI score
of the patients treated showed a dose-response effect, with patients having
received the highest dose showing the greatest improvement in PASI score. In
addition, in self-assessment evaluations, 70% of patients having completed the
12 weeks of treatment stated that their condition had improved with the
administration of /E-941/Neovastat.
Study details. The study on /E-941/Neovastat was a randomized, parallelarm, dose-comparison study for the evaluation of the safety, tolerability and
efficacy of /E-941/Neovastat administered orally for 12 weeks in patients with
moderate to severe psoriasis. A total of 49 patients were recruited for the trial,
with patient enrollment starting in January 1998 and ending in July 1998.
Patients were given between 30 mL and 240 mL/day for 12 weeks, followed by
a 12-week period without treatment. The primary end point of efficacy was
based primarily on the PASI (Psoriasis Area and Severity Index) scoring system
at pre-determined intervals during the trial. /E-941/Neovastat showed a
positive dose dependent effect, with patients receiving the highest dose
compared to the lowest dose showing statistically significant improvement in
PASI score. /E-941/Neovastat was well tolerated at all doses tested and no
serious adverse events were reported during the study.
O phthalm ology
The main target in ophthalmology is age-related macular degeneration. The
objectives of the Phase I monotherapy trial were to determine the safety and

tolerability of /E-941/Neovastat and the most effective dosage for further
clinical trials. This study was a single-center Canadian study involving 10
patients. The results of this study, presented in December 1999, established
the safety and tolerability of the compound and provided evidence of a doseresponse effect.
Study details. A dose titration study was conducted to evaluate the safety,
tolerability and efficacy of/E-941/Neovastat which was administered orally for
30 weeks in age-related macular degeneration patients for whom no standard
therapies were available. The objectives of the study were to assess the safety
and tolerability of/E-941/Neovastat in these patients, and to evaluate the
effects of/E-941/Neovastat on progression of neovascularization in the eye and
its impact on the visual acuity in such patients. Each patient was initially
treated with a dose of 30 mL/day for six weeks. Based on response, the dose
was doubled gradually every six weeks up to 240 mL/day.
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Appendix iii
INFORMED CONSENT
STUDY OF THE BIO ACTIVITY OF SHARK CARTILAGE
I freely and voluntarily consent to be a blood donor in the research project entitled Study o f the
B io a c tiv ity o f S h a rk C a rtila g e to be conducted at Florida International University (University Park
cam pus) during the Summer, Fall and Spring Semesters, 1999-2000, with Sylvia L. Smith as Principal
Investigator. I have been told that this procedure will last approximately five (5) minutes.
I understand that the purpose o f this research is to examine the effect o f shark cartilage extracts
on various functional parameters o f human peripheral blood leukocytes.
I understand that the research procedure will involve donating approximately 25 ml (no more than
30 ml) o f blood on a bi-w eekly basis for the purpose o f isolating blood leukocytes to set up in vitro cell
cultures. Blood will be obtained by venipuncture and drawn by a person licensed to perform phlebotomy
by the State o f Florida. The procedure will be as follows: a tourniquet will be applied to the upper arm to
increase stasis and the phlebotom ist might use the tip o f the index finger to palpate the vein (median
cubital, cephalic or basilic vein), after cleansing the area o f skin at the bend o f the elb ow with a 70%
isopropyl alcohol swab, the phlebotom ist, using the appropriate fine gauge needle, w ill puncture the skin
and insert the needle into the vein. The experience will feel like a pin prick or that o f an injection. Blood
w ill be gently withdrawn into the appropriate collecting tubes. The tourniquet will be released before the
n eedle is withdrawn from the arm and im m ediately pressure will be applied to the site o f the puncture
wound. A very small amount o f blood (less than a drop) may flow after removal o f the needle. The area
w ill be cleansed and a protective band aid applied.
I understand that there are no known benefits involved in my participation in this experiment.
H ow ever, I understand that the fo llo w in g risks m ay be involved in m y participation in this experiment.
O ccasionally, volunteers experience a slight dizziness, mild nausea, or fainting spell. On rare occasions
the procedure might result in the formation o f a hematoma at the site o f puncture, w hich usually resolves
naturally within a w eek. I understand that no com pensation is available from Florida International
University or any o f its agents should som e injury occur. I have been told there will be up to four (4)
volunteer blood donors in this study.
1 understand that I m ay withdraw m y consent and discontinue participation in this research
project at any time with no negative consequ en ces. I have been given the right to ask questions
concerning the procedure, and any questions have been answered to m y satisfaction.
I understand that if I desire further information about this research I should contact Sylvia L.
Smith at 3 0 5 -3 4 8 -3 1 8 3 . I have been offered a co p y o f this informed consent form.
I have read and understand the above.

Participant's signature

Date

I have explained and defined in detail the research procedure in which the participant has agreed to
participate, and I have offered him/her a c o p y o f this informed consent form.

Principal Investigator's signature

Date

A p p en dix iv
Reagents and Chemicals
Supplier

Catalog number

Item

161-0716

Tris

161-0301

SDS

22400-089

RPMI-1640 w/ HEPES

10082-139

Fetal bovine serum

13139

PMA

15140-122

Penicillin-Streptomycin

15581-044

TBE

15558-042

TAE

15585-011

Ethidium bromide

15612-013

Hind III DNA fragments

A507-500

Acedic acid, glacial

S271-500

Sodium chloride, crystal

A142-212

Hydrochloric acid

Bio-Rad

Life Technologies

Fisher Scientific

Hema 3 staining system

Supplier

Catalog number

Item

AO169

Agarose, Type 1-A

D-8779

Dimethyl sulfoxide (DMSO)

T8154

Trypan Blue

M2128

MTT

210-50

E-Toxate kit

H3149

Heparin

D5251

Dextran (MW 500,000)

H1077-1

Histopaque-1077

T4428

Toluene

S4400

Staurosporine

C9911

Camptothecin

C5275

ConA

L6386

LPS

EH2-TNFA

Human TNF-a ELISA kit

EH2-IL4

Human IL-4 ELISA kit

EH-IFNG

Human IFN-y ELISA kit

Sigma

EndogenInc

Solgar Laboratories

Shark cartilage

Supplier

Catalog number

Item

23225

BCA protein assay kit

1-835-246

DNA ladder kit

Pierce

Roche Diagnostics

